US20170136126A1 - Medication With A Reduced Bitter Taste Perception - Google Patents
Medication With A Reduced Bitter Taste Perception Download PDFInfo
- Publication number
- US20170136126A1 US20170136126A1 US15/421,467 US201715421467A US2017136126A1 US 20170136126 A1 US20170136126 A1 US 20170136126A1 US 201715421467 A US201715421467 A US 201715421467A US 2017136126 A1 US2017136126 A1 US 2017136126A1
- Authority
- US
- United States
- Prior art keywords
- polyquaternium
- another example
- medication
- bitterness
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 229940079593 drug Drugs 0.000 title claims abstract description 86
- 235000019611 bitter taste sensations Nutrition 0.000 title 1
- 230000030812 sensory perception of bitter taste Effects 0.000 title 1
- 229920000691 Poly[bis(2-chloroethyl) ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] Polymers 0.000 claims abstract description 77
- 235000019658 bitter taste Nutrition 0.000 claims abstract description 64
- 239000007788 liquid Substances 0.000 claims abstract description 35
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 31
- 108091005708 gustatory receptors Proteins 0.000 claims description 23
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 17
- 229920000289 Polyquaternium Polymers 0.000 claims description 16
- 229960002146 guaifenesin Drugs 0.000 claims description 14
- 229960001802 phenylephrine Drugs 0.000 claims description 14
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 14
- 238000000099 in vitro assay Methods 0.000 claims description 12
- 229960005489 paracetamol Drugs 0.000 claims description 11
- 239000000739 antihistaminic agent Substances 0.000 claims description 10
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 9
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 9
- 229940124641 pain reliever Drugs 0.000 claims description 9
- 244000145321 Acmella oleracea Species 0.000 claims description 8
- 230000001387 anti-histamine Effects 0.000 claims description 8
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
- 230000000954 anitussive effect Effects 0.000 claims description 6
- 229940124584 antitussives Drugs 0.000 claims description 6
- 229960001803 cetirizine Drugs 0.000 claims description 6
- 229960002036 phenytoin Drugs 0.000 claims description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 5
- 229960000381 omeprazole Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 73
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 60
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 22
- 229960004063 propylene glycol Drugs 0.000 description 20
- 235000013772 propylene glycol Nutrition 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 16
- 239000000796 flavoring agent Substances 0.000 description 16
- 235000019634 flavors Nutrition 0.000 description 16
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 14
- 229960001985 dextromethorphan Drugs 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 229960005150 glycerol Drugs 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- 238000002483 medication Methods 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 12
- 235000019534 high fructose corn syrup Nutrition 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229960004106 citric acid Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 9
- -1 erthritol Chemical compound 0.000 description 9
- 235000003599 food sweetener Nutrition 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 229960002920 sorbitol Drugs 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229920001285 xanthan gum Polymers 0.000 description 7
- 239000004376 Sucralose Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 229960003291 chlorphenamine Drugs 0.000 description 6
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 6
- 229940081974 saccharin Drugs 0.000 description 6
- 235000019204 saccharin Nutrition 0.000 description 6
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 6
- 235000019408 sucralose Nutrition 0.000 description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 6
- 150000005846 sugar alcohols Chemical class 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 229960000520 diphenhydramine Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 229950010450 pseudophedrine Drugs 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 235000010493 xanthan gum Nutrition 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 5
- 229940082509 xanthan gum Drugs 0.000 description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 4
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical class OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 206010039424 Salivary hypersecretion Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229960005178 doxylamine Drugs 0.000 description 4
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 4
- 229960005008 doxylamine succinate Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229960000930 hydroxyzine Drugs 0.000 description 4
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229960003910 promethazine Drugs 0.000 description 4
- 229940085605 saccharin sodium Drugs 0.000 description 4
- 208000026451 salivation Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000011083 sodium citrates Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008122 artificial sweetener Substances 0.000 description 3
- 235000021311 artificial sweeteners Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 description 3
- 229960004472 clofedanol Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 3
- 229960002777 dicycloverine Drugs 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 3
- 229960004166 diltiazem Drugs 0.000 description 3
- 229960005426 doxepin Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- MAGQQZHFHJDIRE-BNFZFUHLSA-N pellitorine Chemical compound CCCCC\C=C\C=C\C(=O)NCC(C)C MAGQQZHFHJDIRE-BNFZFUHLSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 2
- ZYTMANIQRDEHIO-KXUCPTDWSA-N (-)-Isopulegol Natural products C[C@@H]1CC[C@@H](C(C)=C)[C@H](O)C1 ZYTMANIQRDEHIO-KXUCPTDWSA-N 0.000 description 2
- LMXFTMYMHGYJEI-IWSPIJDZSA-N (1R,2R,5R)-2-(1-hydroxy-1-methylethyl)-5-methylcyclohexanol Chemical compound C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 LMXFTMYMHGYJEI-IWSPIJDZSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 2
- MDVYIGJINBYKOM-UHFFFAOYSA-N 3-[[5-Methyl-2-(1-methylethyl)cyclohexyl]oxy]-1,2-propanediol Chemical compound CC(C)C1CCC(C)CC1OCC(O)CO MDVYIGJINBYKOM-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- INAXVXBDKKUCGI-UHFFFAOYSA-N 4-hydroxy-2,5-dimethylfuran-3-one Chemical compound CC1OC(C)=C(O)C1=O INAXVXBDKKUCGI-UHFFFAOYSA-N 0.000 description 2
- IUFQZPBIRYFPFD-UHFFFAOYSA-N 5-ethyl-3-hydroxy-4-methyl-2(5H)-furanone Chemical compound CCC1OC(=O)C(O)=C1C IUFQZPBIRYFPFD-UHFFFAOYSA-N 0.000 description 2
- OALYTRUKMRCXNH-UHFFFAOYSA-N 5-pentyloxolan-2-one Chemical compound CCCCCC1CCC(=O)O1 OALYTRUKMRCXNH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 2
- 239000001329 FEMA 3811 Substances 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical class C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- 241000206469 Pulsatilla Species 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- 206010040744 Sinus headache Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001062 anti-nausea Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 2
- 229960000782 bismuth subsalicylate Drugs 0.000 description 2
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229960001271 desloratadine Drugs 0.000 description 2
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- IFYYFLINQYPWGJ-UHFFFAOYSA-N gamma-decalactone Chemical compound CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- PQLMXFQTAMDXIZ-UHFFFAOYSA-N isoamyl butyrate Chemical compound CCCC(=O)OCCC(C)C PQLMXFQTAMDXIZ-UHFFFAOYSA-N 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229930007503 menthone Natural products 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940054194 mucinex Drugs 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 2
- 235000010434 neohesperidine DC Nutrition 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 235000019533 nutritive sweetener Nutrition 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- QSRAJVGDWKFOGU-WBXIDTKBSA-N rebaudioside c Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]1(CC[C@H]2[C@@]3(C)[C@@H]([C@](CCC3)(C)C(=O)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)CC3)C(=C)C[C@]23C1 QSRAJVGDWKFOGU-WBXIDTKBSA-N 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- BXOCHUWSGYYSFW-HVWOQQCMSA-N spilanthol Chemical compound C\C=C\C=C/CC\C=C\C(=O)NCC(C)C BXOCHUWSGYYSFW-HVWOQQCMSA-N 0.000 description 2
- 210000000108 taste bud cell Anatomy 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- PHXATPHONSXBIL-UHFFFAOYSA-N xi-gamma-Undecalactone Chemical compound CCCCCCCC1CCC(=O)O1 PHXATPHONSXBIL-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- PXLKJWMSFPYVNB-UHFFFAOYSA-N (1-methyl-4-propan-2-ylcyclohexyl) acetate Chemical compound CC(C)C1CCC(C)(OC(C)=O)CC1 PXLKJWMSFPYVNB-UHFFFAOYSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- WEUCDJCFJHYFRL-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WEUCDJCFJHYFRL-UHFFFAOYSA-N 0.000 description 1
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GTMKUOPSEMUACB-UHFFFAOYSA-N 2-(1-methyl-4-propan-2-ylcyclohexyl)oxyethanol Chemical compound CC(C)C1CCC(C)(OCCO)CC1 GTMKUOPSEMUACB-UHFFFAOYSA-N 0.000 description 1
- RADIRXJQODWKGQ-HWKANZROSA-N 2-Ethoxy-5-(1-propenyl)phenol Chemical compound CCOC1=CC=C(\C=C\C)C=C1O RADIRXJQODWKGQ-HWKANZROSA-N 0.000 description 1
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical class C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LTPZLDNFECOIQY-UHFFFAOYSA-N 2-methyl-3-(1-methyl-4-propan-2-ylcyclohexyl)oxypropane-1,2-diol Chemical compound CC(C)C1CCC(C)(OCC(C)(O)CO)CC1 LTPZLDNFECOIQY-UHFFFAOYSA-N 0.000 description 1
- MDVYIGJINBYKOM-IBSWDFHHSA-N 3-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxypropane-1,2-diol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO MDVYIGJINBYKOM-IBSWDFHHSA-N 0.000 description 1
- DARSINVAIIMSIF-UHFFFAOYSA-N 3-methyl-4-pyrrolidin-1-yl-2h-furan-5-one Chemical compound O=C1OCC(C)=C1N1CCCC1 DARSINVAIIMSIF-UHFFFAOYSA-N 0.000 description 1
- BLILOGGUTRWFNI-GRYCIOLGSA-N 4-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxy-4-oxobutanoic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCC(O)=O BLILOGGUTRWFNI-GRYCIOLGSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- PJUYQWIDNIAHIZ-UHFFFAOYSA-N 4-methyldiphenhydramine Chemical compound C=1C=C(C)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 PJUYQWIDNIAHIZ-UHFFFAOYSA-N 0.000 description 1
- CTMTYSVTTGVYAW-FRRDWIJNSA-N 5-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxy-5-oxopentanoic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(O)=O CTMTYSVTTGVYAW-FRRDWIJNSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 description 1
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 241000219106 Bryonia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 244000284152 Carapichea ipecacuanha Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000208698 Drosera Species 0.000 description 1
- 229930186291 Dulcoside Natural products 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000001776 FEMA 4720 Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000735432 Hydrastis canadensis Species 0.000 description 1
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 description 1
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XMLSXPIVAXONDL-PLNGDYQASA-N Jasmone Chemical compound CC\C=C/CC1=C(C)CCC1=O XMLSXPIVAXONDL-PLNGDYQASA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186866 Lactobacillus thermophilus Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000007443 Lobaria pulmonaria Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- KNVPMEZIMFVWMD-UHFFFAOYSA-N Menthyl pyrrolidone carboxylate Chemical compound CC(C)C1CCC(C)CC1OC(=O)N1C(=O)CCC1 KNVPMEZIMFVWMD-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- ICKFFNBDFNZJSX-UHFFFAOYSA-N N'-[(4-chlorophenyl)methyl]-N,N-dimethyl-N'-(2-pyridinyl)ethane-1,2-diamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)C=C1 ICKFFNBDFNZJSX-UHFFFAOYSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical class C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000756012 Pelargonium sidoides Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000485664 Protortonia cacti Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 1
- 206010052251 Respiratory tract congestion Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000004284 Rumex crispus Species 0.000 description 1
- 235000021501 Rumex crispus Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000007892 Spilanthes oleracea Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- RCGYDFVCAAKKNG-UHFFFAOYSA-N Thenyldiamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC=1C=CSC=1 RCGYDFVCAAKKNG-UHFFFAOYSA-N 0.000 description 1
- HRYJPHOTGFERGT-UHFFFAOYSA-N Thonzylamine hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CC=N1 HRYJPHOTGFERGT-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BGKAKRUFBSTALK-UHFFFAOYSA-N Vanillin isobutyrate Chemical compound COC1=CC(C=O)=CC=C1OC(=O)C(C)C BGKAKRUFBSTALK-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000009932 Zanthoxylum simulans Nutrition 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UJNOLBSYLSYIBM-NOOOWODRSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2s)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@H](C)O UJNOLBSYLSYIBM-NOOOWODRSA-N 0.000 description 1
- 0 [1*]CCCC/C=C/C=C/C(=O)N1[2*][3*]1 Chemical compound [1*]CCCC/C=C/C=C/C(=O)N1[2*][3*]1 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229940023032 activated charcoal Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BXOCHUWSGYYSFW-UHFFFAOYSA-N all-trans spilanthol Natural products CC=CC=CCCC=CC(=O)NCC(C)C BXOCHUWSGYYSFW-UHFFFAOYSA-N 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical class NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000270 behind-the-counter-drug Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- POIARNZEYGURDG-FNORWQNLSA-N beta-damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 description 1
- POIARNZEYGURDG-UHFFFAOYSA-N beta-damascenone Natural products CC=CC(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-UHFFFAOYSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229960004645 bismuth subcitrate Drugs 0.000 description 1
- 229960003166 bromazine Drugs 0.000 description 1
- NUNIWXHYABYXKF-UHFFFAOYSA-N bromazine Chemical compound C=1C=C(Br)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 NUNIWXHYABYXKF-UHFFFAOYSA-N 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical class C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 239000001405 butyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- OHHIVLJVBNCSHV-KTKRTIGZSA-N butyl cinnamate Chemical compound CCCCOC(=O)\C=C/C1=CC=CC=C1 OHHIVLJVBNCSHV-KTKRTIGZSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WKRWUYKLUMMAKG-WYGBAUISSA-L calcium;(4r,6s,8s,10z,12r,14r,16e,18r,19r,20s,21s)-19,21-dihydroxy-22-[(2s,5s)-5-[(2r,5s)-5-[(1r)-1-hydroxyethyl]-5-methyloxolan-2-yl]-5-methyloxolan-2-yl]-4,6,8,12,14,18,20-heptamethyl-11-oxido-9-oxodocosa-10,16-dienoate Chemical compound [Ca+2].O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/[O-])=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC([O-])=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 WKRWUYKLUMMAKG-WYGBAUISSA-L 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004831 chlorcyclizine Drugs 0.000 description 1
- 229960001448 chloropyramine Drugs 0.000 description 1
- XAEXSWVTEJHRMH-UHFFFAOYSA-N chloropyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 description 1
- 229950005434 chloropyrilene Drugs 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- IVLCENBZDYVJPA-ARJAWSKDSA-N cis-Jasmone Natural products C\C=C/CC1=C(C)CCC1=O IVLCENBZDYVJPA-ARJAWSKDSA-N 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical class CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229950002020 clemizole Drugs 0.000 description 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 1
- ZSQANMZWGKYDER-JXMROGBWSA-N clocinizine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 ZSQANMZWGKYDER-JXMROGBWSA-N 0.000 description 1
- 229960003826 clocinizine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960004073 deptropine Drugs 0.000 description 1
- ZWPODSUQWXAZNC-PMOLBWCYSA-N deptropine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2C1O[C@H](C1)C[C@H]2CC[C@@H]1N2C ZWPODSUQWXAZNC-PMOLBWCYSA-N 0.000 description 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical class C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
- 229960002691 dexbrompheniramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- HSXUHWZMNJHFRV-UHFFFAOYSA-L disodium;6-oxido-5-phenyldiazenyl-4-sulfonaphthalene-2-sulfonate Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1N=NC1=CC=CC=C1 HSXUHWZMNJHFRV-UHFFFAOYSA-L 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- URSRSKSNFPUKGH-UHFFFAOYSA-N embramine Chemical compound C=1C=C(Br)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 URSRSKSNFPUKGH-UHFFFAOYSA-N 0.000 description 1
- 229950000472 embramine Drugs 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940005667 ethyl salicylate Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000001902 eugenia caryophyllata l. bud oil Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical class C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- IFYYFLINQYPWGJ-VIFPVBQESA-N gamma-Decalactone Natural products CCCCCC[C@H]1CCC(=O)O1 IFYYFLINQYPWGJ-VIFPVBQESA-N 0.000 description 1
- OALYTRUKMRCXNH-QMMMGPOBSA-N gamma-Nonalactone Natural products CCCCC[C@H]1CCC(=O)O1 OALYTRUKMRCXNH-QMMMGPOBSA-N 0.000 description 1
- PHXATPHONSXBIL-JTQLQIEISA-N gamma-Undecalactone Natural products CCCCCCC[C@H]1CCC(=O)O1 PHXATPHONSXBIL-JTQLQIEISA-N 0.000 description 1
- 229940020436 gamma-undecalactone Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000005679 goldenseal Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 229950008315 homochlorcyclizine Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- LHFKHAVGGJJQFF-UHFFFAOYSA-N hydroxyl-alpha-sanshool Natural products CC=CC=CC=CCCC=CC(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229930002839 ionone Natural products 0.000 description 1
- 150000002499 ionone derivatives Chemical class 0.000 description 1
- 229960005208 ipecacuanha Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 229940094941 isoamyl butyrate Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical group C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- PTVWPYVOOKLBCG-ZDUSSCGKSA-N levodropropizine Chemical compound C1CN(C[C@H](O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-ZDUSSCGKSA-N 0.000 description 1
- 229960002265 levodropropizine Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical class C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004018 magaldrate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000012243 magnesium silicates Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 239000001699 mentha arvensis leaf oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- BVIDQAVCCRUFGU-UHFFFAOYSA-M methyl sulfate;trimethyl(1-phenothiazin-10-ylpropan-2-yl)azanium Chemical compound COS([O-])(=O)=O.C1=CC=C2N(CC(C)[N+](C)(C)C)C3=CC=CC=C3SC2=C1 BVIDQAVCCRUFGU-UHFFFAOYSA-M 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- BBIMHFSPNXQFAH-UHFFFAOYSA-N moxastine Chemical compound C=1C=CC=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 BBIMHFSPNXQFAH-UHFFFAOYSA-N 0.000 description 1
- 229950001894 moxastine Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- ZVKDZYPEJXGLJG-UHFFFAOYSA-N n-tert-butyl-5-methyl-2-propan-2-ylcyclohexane-1-carboxamide Chemical compound CC(C)C1CCC(C)CC1C(=O)NC(C)(C)C ZVKDZYPEJXGLJG-UHFFFAOYSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- ZYTMANIQRDEHIO-UHFFFAOYSA-N neo-Isopulegol Natural products CC1CCC(C(C)=C)C(O)C1 ZYTMANIQRDEHIO-UHFFFAOYSA-N 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229930006948 p-menthane-3,8-diol Natural products 0.000 description 1
- 150000002936 p-menthane-3,8-diol derivatives Chemical class 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000010663 parsley oil Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940033617 pediacare Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 description 1
- 229960004439 pemirolast Drugs 0.000 description 1
- 229950011188 pentigetide Drugs 0.000 description 1
- KQDIGHIVUUADBZ-PEDHHIEDSA-N pentigetide Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KQDIGHIVUUADBZ-PEDHHIEDSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 description 1
- 229960001526 phenyltoloxamine Drugs 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- ZYIBVBKZZZDFOY-UHFFFAOYSA-N phloxine O Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 ZYIBVBKZZZDFOY-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229950010674 picumast Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960002775 pyrrobutamine Drugs 0.000 description 1
- WDYYVNNRTDZKAZ-XDHOZWIPSA-N pyrrobutamine Chemical compound C1=CC(Cl)=CC=C1C\C(C=1C=CC=CC=1)=C/CN1CCCC1 WDYYVNNRTDZKAZ-XDHOZWIPSA-N 0.000 description 1
- TVRGPOFMYCMNRB-UHFFFAOYSA-N quinizarine green ss Chemical compound C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1 TVRGPOFMYCMNRB-UHFFFAOYSA-N 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 229950009147 repirinast Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960005328 rupatadine Drugs 0.000 description 1
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- VBSPHZOBAOWFCL-UHFFFAOYSA-N setastine Chemical compound C=1C=CC=CC=1C(C=1C=CC(Cl)=CC=1)(C)OCCN1CCCCCC1 VBSPHZOBAOWFCL-UHFFFAOYSA-N 0.000 description 1
- 229950003911 setastine Drugs 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 229940062830 spongia tosta Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940066768 systemic antihistamines aminoalkyl ethers Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LCAAMXMULMCKLJ-UHFFFAOYSA-N talastine Chemical compound C12=CC=CC=C2C(=O)N(CCN(C)C)N=C1CC1=CC=CC=C1 LCAAMXMULMCKLJ-UHFFFAOYSA-N 0.000 description 1
- 229960002742 talastine Drugs 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 description 1
- 229950010257 terpin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002304 thenalidine Drugs 0.000 description 1
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 1
- 229960004283 thenyldiamine Drugs 0.000 description 1
- 229960004636 thonzylamine hydrochloride Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960000737 tolpropamine Drugs 0.000 description 1
- CINROOONPHQHPO-UHFFFAOYSA-N tolpropamine Chemical compound C=1C=C(C)C=CC=1C(CCN(C)C)C1=CC=CC=C1 CINROOONPHQHPO-UHFFFAOYSA-N 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- VVGOCOMZRGWHPI-UHFFFAOYSA-N trans-hept-4-enal Natural products CCC=CCCC=O VVGOCOMZRGWHPI-UHFFFAOYSA-N 0.000 description 1
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 description 1
- 229950011638 traxanox Drugs 0.000 description 1
- MLCGWPUVZKTVLO-UHFFFAOYSA-N traxanox Chemical compound C=1C(C(C2=CC=CN=C2O2)=O)=C2C(Cl)=CC=1C=1N=NNN=1 MLCGWPUVZKTVLO-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical class C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960002634 tritoqualine Drugs 0.000 description 1
- IRGJVQIJENCTQF-UHFFFAOYSA-N tritoqualine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=C(OCC)C(OCC)=C(OCC)C(N)=C2C(=O)O1 IRGJVQIJENCTQF-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007850 β-damascenone Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
Definitions
- the present invention relates to a liquid medication comprising a low molecular weight polyquaternium to modulate bitterness, more particularly a low level of polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 to modulate bitterness.
- bitter There are five recognized taste sensations, sweet, salty, sour, bitter, and umami. Many people dislike things that are overly bitter and perceive it is as unpleasant, sharp, or otherwise disagreeable. Bitterness is the most sensitive of the tastes and it is thought to be a defense mechanism to protect the body against ingestion of toxic substances, as a large number of natural bitter compounds are known to be toxic.
- a liquid medication with reduced bitterness comprising: (a) a drug active; and (b) a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof.
- a liquid medication with reduced bitterness comprising: (a) a drug active selected from the group consisting of guaifenesin, phenytoin, omeprazole, cetirizine, jambu, acetaminophen, and combinations thereof; (b) a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof; wherein an overall bitterness is reduced by at least about 40% as compared to an identical composition without the polyquaternium as determined by the in vitro Assay for Taste Receptors; and wherein an overall bitterness is less than about 6500 fluorescence units as determined by the in vitro Assay for Taste Receptors.
- a dose of liquid medication with reduced bitterness comprising: (a) at least about 200 mg guaifenesin; (b) from about 0.05% to about 0.2% of a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof; wherein a Descriptive Profile Panel of in mouth bitter is reduced by at least about 25% as compared to an in mouth bitter of an identical composition without the polyquaternium.
- FIG. 1A shows the molecular structure for polyquaternium-2
- FIG. 1B shows the molecular structure for polyquaternium-17
- FIG. 1C shows the molecular structure for polyquaternium-18
- FIG. 2 compares the modulation of bitterness of solutions with different water soluble polymers in an Assay for Taste Receptors
- FIG. 3 compares the modulation of bitterness of solutions with different water soluble polymers in an Assay for Taste Receptors
- FIG. 4A compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors
- FIG. 4B compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors
- FIG. 4C compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors
- FIG. 4D compares the modulation of bitterness of solutions containing an active or an excipient and a concentration of polyquaternium-2 in an Assay for Taste Receptors
- FIG. 5 compares the modulation of bitterness of full formulations containing one or more actives and excipients in an Assay for Taste Receptors
- FIG. 6 shows the Descriptive Profile Panel (DPP) bitter intensity of six different compositions containing a high fructose corn syrup (HFCS) base, guaifenesin, and different concentrations of polyquaternium-2; and
- DPP Descriptive Profile Panel
- FIG. 7 shows the Descriptive Profile Panel (DPP) bitter intensity of two examples that both contain four actives and one example contains polyquaternium-2.
- DPP Descriptive Profile Panel
- Polyquaternium-2 modulated the bitterness of guaifenesin (GG) in the cell assays better than any other polymer, including the polyquats which have a similar chemical structure.
- Polyquaternium-17 and/or polyquaternium-18 are structurally analogous to polyquternium-2 and can be used instead of or in combination with polyquaternium-2.
- polyquaternium-2 significantly reduced the bitterness of GG, one of the most bitter actives, based on the in vitro assays, it does not modulate the bitterness of all actives to the same extent.
- polyquaternium-2 significantly modulated the bitterness of phenytoin, omeprazole, jambu extract and acetaminophen (APAP), but had little effect on bitter actives such as dicyclomine, hydroxyzine, promethazine, doxepin, and diphenhydramine.
- polyquaternium-2 modulated bitterness better at the relatively low concentration of about 0.1%, as compared to higher concentrations.
- dose refers to a volume of medication, such as liquid medication, containing an amount of a drug active suitable for administration on a single occasion, according to sound medical practice.
- a dose can be orally administered.
- a dose can be about 30 mL, in another example about 25 mL, in another example about 20 mL, in another example about 15 mL, and in another example about 10 mL.
- a dose of liquid medication can be from about 10 mL to about 75 mL, in another example from about 15 mL to about 50 mL, in another example from about 25 mL to about 40 mL, and in another example from about 28 mL to about 35 mL.
- the concentration of active ingredients can be adjusted to provide the proper doses of actives given the liquid dose size.
- the dose is intended to be administered every 4 hours, in another example every 6 hours, in another example every 8 hours, and in another example every 12 hours.
- medication refers to medications, such as pharmaceuticals, including prescription medications, over-the-counter medications, behind-the-counter medications and combinations thereof.
- a medication can be a supplement.
- compositions the present invention can contain, consist of, or consist essentially of, the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in dosage forms intended for use or consumption by humans.
- polyquaternium-2 can be added to compositions, particularly liquid medications, to reduce bitterness.
- Polyquaternium-2 has the CAS Registry Number 68555-36- 2 and the chemical name is Poly[bis(2-chloroethyl) ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] and is commercially available as Mirapol® A 15 (available from Rhodia, Cranbury, N.J.).
- the molecular structure for polyquaternium-2 is shown in FIG. 1A .
- Polyquaternium-17 (CAS Registry Number 148506-50-7) and polyquaternium-18 (CAS Registry Number 113784-58-0) are structurally analogous to polyquaternium-2 and can be used in addition to or instead of polyquaternium-2 to modulate bitter.
- the molecular structure for polyquaternium-17 is shown in FIG. 1B and the molecular structure for polyquaternium-18 is shown in FIG. 1C .
- FIG. 2 compares the modulation of bitterness of a control solution comprising 2 mM guaifenesin (GG) with solutions comprising 2 mM GG and one of seven water soluble polymers at concentrations ranging from 0.33% to 0.01%.
- the results for FIG. 2 are from an in vitro Assay for Taste Receptors, as described hereafter.
- the cell cultures and assays provide an in vitro method to screen for bitterness that can mimic an in vivo response.
- the water soluble polymers that were tested were as follows at concentrations ranging from 0.01% to 0.33%:
- the taste receptors were activated as described in the Assay for Taste Receptors herein.
- the observed activation is presented as a % of the control value.
- the control value is activation by a 2 mM GG solution with no added polymers.
- the results from this assay showed that only Polyquaternium-2 completely blocked the activation of taste cell receptors by GG. This is especially surprising, since GG is one of the most bitter actives used in liquid medications.
- Other polymers, including polyquaternium-6 and polyquaternium D16 (Luviquat® 905) also showed some reduction, however the modulation was not dose dependent.
- FIG. 3 compares the modulation of bitterness of a solution comprising 2 mM GG with one of four water soluble polymers at concentrations ranging from 0.01% to 0.00003%.
- the four water soluble polymers were polyquaternium-6 (Mirapol® 100), polyquaternium-2 (Mirapol® A15), polyquaternium D16 (Luviquat® FC 550), and polyquaternium D16 (Luviquat® FC 905).
- the same Assay for Taste Receptor Method described herein and for FIG. 2 was used to generate the results for FIG. 3 .
- the lower concentrations of polymer were selected to help further differentiate the potential ability for the polymers to provide bitter blocking in vivo.
- polyquaternium-2 provided the greatest reduction in bitterness of the 2 mM GG solution. At 0.01%, the bitterness was reduced to less than 20% of the bitterness of the control. Furthermore, polyquaternium-2 was the only composition that showed dose dependent blocking.
- polyquaternium-2 was effective in blocking the bitterness in the Assay for Taste Receptors, it was desirable to understand if polyquaternium-2 was effective against all bitter actives or select bitter actives. As shown in FIGS. 4A, 4B, and 4C , it was found that polyquaternium-2 only blocked certain bitter drug actives and had little to no effect on others.
- FIGS. 4A, 4B, and 4C compare the modulation of bitterness, if any, of solutions containing an active and a concentration of polyquaternium-2.
- concentration of polyquaternium-2 ranges from 0.00041% to 0.1%.
- GG at a concentration of 2 mM without polyquaternium-2 is used as a control.
- the actives were selected because they are frequently used in medications and are known to be bitter.
- the results for FIGS. 4A, 4B, and 4C are from an in vitro Assay for Taste Receptors as described hereafter.
- FIG. 4A compares the modulation of bitterness, if any, of solutions comprising 250 ⁇ M active and a concentration of polyquaternium-2.
- the actives in FIG. 4A are dicyclomine, hydroxyzine, promethazine, doxepin, and 2 mM GG.
- FIG. 4A shows that polyquaternium-2 has at best a very weak bitter blocking activity on dicyclomine, hydroxyzine, promethazine, and doxepin.
- FIG. 4A does not show a dose dependent effect and thus polyquaternium-2 is probably not a specific blocker of these actives.
- the actives in FIG. 4B are 1 mM diltiazem, 2 mM phenytoin, and 1 mM diphenhydramine.
- Polyquaternium-2 blocked some of the bitterness of diltiazem, but it doesn't show a dose dependent effect and thus polyquaternium-2 is probably not a specific blocker for diltiazem.
- Polyquaternium-2 strongly blocked the bitterness from phenytoin and omeprazole and polyquaternium-2 had little or no effect on diphenhydramine
- the actives tested in FIG. 4C included 1 mM cetirizine, 1 mM enalapril, 0.25% jambu ( Acmella oleracea ) extract (commercially available as Jambu SE WS from NaturexTM, Southhackensack, N.J.), and 10 mM acetaminophen (APAP).
- Polyquaternium-2 blocked some of the bitterness of cetirizine. Polyquaternium-2 did not show a dose dependent bitter blocking of enalapril. However, polyquaternium-2 shows a strong dose dependent effect on blocking jambu and APAP.
- FIG. 4D compares the modulation of bitterness, if any, of solutions containing an active or an excipient and 0.01% polyquaternium-2 in the in vitro Assay for Taste Receptors as described hereafter.
- the compositions tested were 5 mM pseudoephedrine hydrochloride, 2 mM terpin, 2.5 mM prednisolone, 2.5 mM famotidine, 0.5 mM 1,10-phenanthroline, 0.5 mM erythromycin, 0.5 mM saccharin, 3% propylene glycol, and 2 mM GG was used as the control.
- Polyquaternium-2 modulated the bitterness in all of the compositions, including components that were very bitter, like 1,10-phenanthroline, saccharin, and propylene glycol. Surprisingly, polyquaternium-2 completely blocked the bitterness from saccharin and substantially reduced the bitterness of both propylene glycol and 1,10-phenanthroline.
- polyquaternium-2 polyquaternium-17, and/or polyquternium-18 can reduce the bitterness of a drug active selected from the group consisting of GG, APAP, jambu extract, cetirizine, phenytoin, omeprazol, 1,10-phenanthroline, and combinations thereof.
- FIG. 5 compares ten full formulations diluted to 0.617% with the same ten formulations diluted to 0.617% with 0.02% polyquaternium-2 the in vitro Assay for Taste Receptors as described hereafter.
- the formulations are described in Table 1 below.
- FIG. 6 also includes a formulation with 2 mM GG and 10 ⁇ M Ionomycin, calcium salt, which were both used as controls.
- Phosphorus 12X, Pulsatilla 6X, Sulphur 12X PediaCare ® 5 mL Phenylephrine HCl (2.5 mg) Carboxymethylcellulose Decongestant sodium, citric acid, edetate (Lot # 18263) disodium, FD&C red #40, flavors, glycerin, sodium benzoate, sodium citrate, sorbitol, sucralose, water Chestal ® Honey 2 US tsp Antimonium tartaricum 6C, Citric acid, honey, purified (Lot # M0092897) (9.9 mL) Bryonia 3C, Coccus cacti water, sodium benzoate, 3C, Drosera 3C, sucrose Ipecacuanha 3C, Pulsatilla 6C, Rumex crispus 6C, Spongia tosta 3C, Sticta pulmonaria 3C Nature's Way ®, 7.5 mL Pelargonium sidoides 1X Alcohol (8.2%),
- polyquaternium-2 was effective in substantially reducing or completely reducing the bitterness in all of the full formulations.
- Polyquaternium-2 completely or almost completely reduced the bitter from Nature's Way® UmckaTM ColdCare, the Nighttime Cold & Flu Relief similar to Nyquil® without doxylamine, the Nighttime Cold & Flu Relief similar to Nyquil® cherry flavor without doxylamine, the Nighttime Cold & Flu Relief similar to Alcohol-Free NyQuil® without chlorpheniramine, and DayQuil®.
- the 0.02% polyquaternium-2 significantly reduced the bitterness of DayQuil® Severe and Mucinex® Fast-Max® DM Max.
- polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition by at least about 5% as compared to an identical composition without the polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter, in another example by at least about 10%, in another example by at least about 20%, in another example by at least about 30%, in another example by at least about 40%, in another example by at least about 50%, in another example by at least about 60%, in another example by at least about 65%, in another example by at least about 70%, in another example by at least about 75%, in another example by at least about 80%, in another example by at least about 85%, in another example by at least about 90%, in another example at least about 93%, in another example at least about 95%, in another example by at least about 97%, in another example by at least about 98%, in another example by at least about 99% and in another example by at least about by at
- polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition as compared to an identical composition without the polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter.
- polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition as compared to a composition that contains GG and does not contain polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter.
- the composition can have an overall bitterness of less than about 9000 fluorescence units (FUs) as determined by the in vitro Assay for Taste Receptors as described hereafter, in another example less than about 8500 FUs, in another example less than 8000 FUs, in another example less than 7500 FUs, in another example less than about 7000 FUs, in another example less than about 6500 FUs, in another example less than about 6000 FUs, in another example less than about 5500 FUs, in another example less than about 5000 FUs, in another example less than about 4500 FUs, in another example less than about 4000 FUs, in another example less than about 3500 FUs, in another example less than about 3000 FUs, in another example less than about 2500 FUs, in another example less than about 2000 FUs, in another example less than about 1500 FUs, in another example less than about 1000 FUs, in another example less than about 750 FUs, in another example less than about 500 FUs
- FIG. 6 compares the bitterness, as determined by the DPP panel, of the examples described in the table below.
- the high fructose corn syrup (HFCS) base contains 46.7% HFCS stock, 5.9% PEG-400 (polyethylene glycol 400), 8.6% propylene glycol, 7.4% ethanol, and 30.07% water.
- Excipients, including propylene glycol, can be bitter and the polyquaternium-2 can block the bitterness of the excipients in the HFCS base.
- Example High Fructose Corn Syrup Base Polyquaternium-2 1 q.s. 0% 2 q.s. 1% 3 q.s. 0.3% 4 q.s. 0.1% 5 q.s. 0.03% 6 q.s. 0.01%
- the DPP panel includes panelists that are trained and validated in SpectrumTM Descriptive Analysis methodology and evaluate bitterness on a 60 point scale.
- Example 4 which contained 0.1% polyquaternium-2 was less bitter than Examples 2 and 3, which had higher levels of Polyquaternium-2.
- Examples 5 and 6 were also less bitter than Examples 2 and 3 and may still be acceptable to consumers.
- FIG. 7 compares the bitterness, as determined by the DPP panel, of the following examples:
- the DPP panel for FIG. 7 was conducted according to the procedure described herein for FIG. 6 .
- Polyquaternium-2 reduced the overall bitterness in mouth, after expectoration, and at three minutes.
- the in mouth bitter was reduced by about 50% and the after expectoration bitter was reduced by over 10%.
- the three minute bitter was only reduced slightly and there was not a noticeable difference in bitterness after ten minutes.
- the DPP in mouth bitter is reduced by at least about 5% as compared to the in mouth bitterness of an identical composition without polyquaternium-2, polyquaternium-17, and/or polyquaternium-18, in another example by at least about 10%, in another example by at least about 15%, in another example by at least about 20%, in another example by at least about 25%, in another example by at least about 35%, in another example by at least about 40%, in another example by at least about 45%, and in another example by at least about 50%.
- the DPP after expectoration bitter is reduced by at least about 4% as compared to the in mouth bitterness of an identical composition without polyquaternium-2, polyquaternium-17, and/or polyquaternium-18, in another example by at least about 4%, in another example by at least about 10%, in another example the DPP after expectoration bitterness by at least about 15%, in another example by at least about 18%, in another example by at least about 20%, and in another example by at least about 22%.
- Polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can be added to compositions, in particular liquid pharmaceutical compositions.
- the composition contains from about 0.01% to about 1% polyquaternium-2, in another example from about 0.03% to about 0.3%, in another example from about 0.05% to about 0.2%, in another example from about 0.07% to about 0.15%, in another example from about 0.08% to about 0.13%, and in another example from about 0.09% to about 0.11%.
- the composition can contain about 0.1% polyquaternium-2.
- the composition can contain less than about 1% polyquaternium-2, in another example less than about 0.5%, in another example less than about 0.3%, in another example less than about 0.2%, in another example less than about 0.15%, and in another example less than about 0.12%.
- compositions can include a variety of orally administered dosage forms.
- dosage forms can include a liquid medication, particles suspended in a liquid formulation, a solid in a gelatin or foam, or a solid dose in the form of a tablet, powder, granules, pellets, microspheres, nanospheres, beads, or nonpareils, and combinations thereof.
- the dosage form is a liquid medication. Dosage forms can be orally administered and can be swallowed immediately, slowly dissolved in the mouth, or chewed.
- polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can be added to a medication intended for use by children. Children can be especially sensitive to bitter tastes and adding polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can make bitter medicines more palatable.
- Non-limiting examples of additional solvents can include water, ethanol, glycerol, propylene glycol, polyethylene glycol 400, polyethylene glycol 200, and mixtures thereof.
- the medication comprises from about 40% to about 95% solvent, in another example from about 50% to about 80% solvent, and in another example from about 55% to about 60% solvent, and in another example from about 68% solvent to about 72% solvent.
- the medication can contain water and propylene glycol.
- the medication comprises from about 15% to about 80% water, in another example from about 25% to about 75% water, in another example from about 40% to about 70% water, in another example from about 35% to about 45% water, and in another example from about 57% to about 66% water.
- the medication can contain from about 1% to about 10% propylene glycol, in another example from about 2% to about 8% propylene glycol, and in another example from about 3% to about 6% propylene glycol.
- the medication can contain from about 5% to about 40% propylene glycol, in another example from about 15% to about 35% propylene glycol, and in another example from about 20% to about 30% propylene glycol.
- the medication can comprise from about 1% to about 15% ethanol, in another example from about 3% to about 12% ethanol, and in another example from about 6% to about 10% ethanol.
- compositions can comprise a sweetener to provide sweetness and taste masking of the actives and excipients that provide a bitter character.
- the composition comprises from about 2% to 25% sweetener, in another example from about 5% to 20% sweetener, in another example from about 7% to 15% sweetener, and in another example from about 8% to 12% sweetener.
- sweeteners can include nutritive sweeteners, sugar alcohols, synthetic sugars, high intensity natural sweeteners, and combinations thereof.
- Non-limiting examples of nutritive sweeteners can include fructose, galactose, and combinations thereof.
- the sweetener can be high fructose corn syrup.
- Non-limiting examples of sugar alcohols can include xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erthritol, glycerin, and combinations thereof.
- the composition can comprise from about 1% to about 30% sugar alcohol, in another example from about 5% to about 28% sugar alcohol, in another example about 10% to about 25% sugar alcohol, and in another example about 15% to about 23% sugar alcohol.
- the composition comprises from about 5% to about 20% sorbitol, in another example from about 7% to about 18% sorbitol, and in another example from about 10% to about 15% sorbitol.
- the composition comprises from about 3% to about 15% glycerin, in another example from about 5% to about 10% glycerin, and in another example from about 7% to about 9% glycerin.
- Non-limiting examples of synthetic sweeteners can include sodium saccharin, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, and mixtures thereof.
- the composition can comprise from about 0.01% to about 0.5% artificial sweetener, in another example from about 0.1% to about 0.3% artificial sweetener, and in another example about 0.15% to about 0.25% artificial sweetener.
- Non-limiting examples of high intensity natural sweeteners can include neohesperidin dihydrochalcone, stevioside, rebaudioside A, rebaudioside C, dulcoside, monoammonium glycrrhizinate, thaumatin, and combinations thereof.
- the liquid composition can optionally include one or more sensates.
- sensates can include cooling sensates, warming sensates, tingling sensates, and combinations thereof. Sensates can useful to deliver signals to the user.
- Non-limiting examples of cooling sensates can include WS-23 (2-Isopropyl-N,2,3-trimethylbutyramide), WS-3 (N-Ethyl-p-menthane-3-carboxamide), WS-30 (1-glyceryl-p-mentane -3-carboxylate), WS-4 (ethyleneglycol-p-methane-3-carboxylate), WS-14 (N-t-butyl-p-menthane-3-carboxamide), WS-12 (N-(4-,ethoxyphenyl)-p-menthane-3-carboxamide), WS-5 (Ethyl-3-(p-menthane-3-carboxamido)acetate, Menthone glycerol ketal (sold as Frescolat® MGA by Haarmann & Reimer), ( ⁇ )-Menthyl lactate (sold as Frescolat® ML by Haarmann & Reimer), ( ⁇ )-Menthoxypropane-1
- the cooling sensate can be EverCoolTM 180 available from Givaudan of Cincinnati, Ohio, as a 5% solution of N-(4-cyanomethylphenyl)- ⁇ -menthanecarboxamide in a flavoring ingredient cool white grape, or as a 7.5% solution of N-(4-cyanomethylphenyl)- ⁇ -menthanecarboxamide in a flavor ingredient such as spearmint or peppermint.
- Non-limiting examples of warming sensates can include TK 1000, TK 1 MM, Heatenol—Sensient Flavors, Optaheat—Symrise Flavors, Cinnamon, Capsicum, Capsaicin, Curry, FSI Flavors, Isobutavan, Nonivamide 60162807, Hotact VEE, Hotact 1 MM, piperine, optaheat 295 832, optaheat 204 656, optaheat 200 349, and combinations thereof.
- Warming sensates can be present from about 0.005% to about 2%, in another example from about 0.01% to about 1%, and in another example from about 0.1% to about 0.5%.
- Non-limiting examples of tingling sensates can include sichuan pepper, hydroxy alpha sanshool, jambu extracts, spilanthol, and combinations thereof. In one example, tingling sensates can be present from about 0.005% to about 1%, in another example from about 0.01% to about 0.5%, and another example from about 0.015% to about 0.3%.
- the composition can comprise a flavoring ingredient.
- flavoring ingredients are generally used in the compositions at levels of from about 0.001% to about 8%, by weight of the composition.
- flavoring ingredients can include peppermint oil, corn mint oil, spearmint oil, oil of wintergreen, clove bud oil, cassia, sage, parsley oil, marjoram, lemon, lime, orange, mango, cis-jasmone, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, 5-ethyl-3-hydroxy-4-methyl-2(5H)-furanone, vanillin, ethyl vanillin, propenyl guaethol, heliotropine, 4-cis-heptenal, diacetyl, methyl- ⁇ -tert-butyl phenyl acetate, menthol, methyl salicylate, ethyl salicylate, 1-menthyl acetate, oxanone, alpha-irisone, methyl cinnamate, ethyl cinnamate, butyl cinnamate, ethyl butyrate, ethyl
- suitable flavoring ingredients are those containing structural features and functional groups that are less prone to redox reactions. These include derivatives of flavouring ingredients that are saturated or contain stable aromatic rings or ester groups.
- the composition comprises from about 0.01% to about 1% flavoring ingredients, in another example from about 0.05% to about 0.5% flavoring ingredients, and in another example from about 0.1% to about 0.3% flavoring ingredients.
- composition can optionally include one or more salivation agents.
- salivation agents include formula (I):
- R 1 represents C1-C2 n-alkyl
- R 2 is 2-methyl-1-propyl and R 3 is hydrogen, or R 2 and R 3 taken together is a moiety (designated by the dashed lines) having the formula —(CH 2 )— wherein n is 4 or 5, and combinations thereof.
- the salivating agent comprises a material wherein R 2 is 2-methyl-1-propyl and R 3 is hydrogen
- the salivating agent comprises a material wherein R 1 is Cl n-alkyl, R 2 is 2-methyl-1-propyl and R 3 is hydrogen
- the salivating agent comprises trans-pellitorin, a chemical having a structure according to formula (II):
- the salivation agent can include sodium bicarbonate, sodium chloride, trans-pellitorin, and combinations thereof.
- salivation agents can be present from about 0.05% to about 2%, in another embodiment from about 0.1% to about 1%, and in another example from about 0.25%% to about 0.75%.
- the liquid composition can be any color. Non-limiting examples of colors can include red, green, amber, orange, yellow, blue, pink, violet, turquoise, and combinations thereof. In one example, the composition is green. In another example, the liquid composition is clear.
- the composition can also comprise a dye that provides the color.
- dyes that may be used in the present invention include FD&C blue #1, FD&C blue #2, D&C blue #4, D&C blue #9, FD&C green #3, D&C green #5, D&C green #6, D&C green #8, D&C orange #4, D&C orange #5, D&C orange #10, D&C orange #11, FD&C red #3, FD&C red #4, D&C red #6, D&C red #7, D&C red #17, D&C red #21, D&C red #22, D&C red #27, D&C red #28, D&C red #30, D&C red #31, D&C red #33, D&C red #34, D&C red #36, D&C red #39, FD&C red #40, D&C violet #2, FD&C yellow #5, FD&C yellow #6, D&C yellow #7, Ext.
- the composition comprises from about 0.001% to about 0.1% dye, in another example from about 0.002% to about 0.05% dye, and in another example form about 0.003% to about 0.01% dye.
- the composition comprises a buffer.
- the buffer can help maintain a constant pH within the liquid composition.
- the liquid composition comprises from about 0.05% to about 2% buffer, in another example from about 0.1% to about 1% buffer, in another example from about 0.15% to about 0.5% buffer, and in another example from about 0.18% to about 0.25% buffer.
- Buffers can include acetate buffers, citrate buffers, and phosphate buffers.
- Non-limiting examples of buffers can include acetic acid, sodium acetate, citric acid, sodium citrate, monobasic sodium phosphate, dibasic sodium phosphate, sodium carbonate, sodium bicarbonate, succinic acid, sodium succinate, potassium dihydrogen phosphate, and phosphoric acid.
- the composition comprises a preservative.
- the liquid composition comprises from about 0.01% to about 1% preservative, in another example from about 0.05% to about 0.5% preservative, in another example from about 0.07% to about 0.3% preservative, and in another example from about 0.08% to about 0.15% preservative.
- preservatives can include benzalkonium chloride, ethylenediaminetetraacetic acid (EDTA), benzyl alcohol, potassium sorbate, parabens, benzoic acid, sodium benzoate, and mixtures thereof.
- the composition comprises a thickener.
- the liquid composition comprises from 0.01% to 3% thickener, in another example 0.05% to 1.5% thickener, in another example 0.1% to 0.75% thickener, and in another example 0.12% to 0.3% thickener.
- thickeners can include xanthan gum, carrageenan, polyacrylic acid, polyvinylpyrrolidone, cellulosic polymers including carboxymethycellulose, hydroxethylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, and combinations thereof.
- the liquid compositions can comprise one or more drug actives.
- the drug actives can be immediate release drug actives, extended release drug actives, or delayed release drug actives.
- the drug active can be formulated as particles and in another example the active can be formulated as coated beads.
- the drug active is a multi-symptom relief (MSR) cold/flu active which can be used to treat one or more cold/flu symptoms.
- MSR cold/flu actives can be used to treat a variety of cold/flu symptoms including nasal congestion, runny nose, sneezing, headache, dry cough, sore throat, sinus pressure or pain, chest congestion, muscle aches/pains, wet/chesty cough, fever, and combinations thereof.
- MSR cold/flu actives can include decongestants, expectorants, antihistamines, antitussives, pain relievers, and combinations thereof.
- MSR cold/flu actives can be formulated for daytime use or nighttime use.
- the liquid medication comprises instructions that direct a user to ingest the medication at night before bedtime.
- Non-limiting examples of expectorants can include guaifenesin, ambroxol, bromhexine, and combinations thereof.
- the expectorant can be guaifenesin.
- a dose can comprise 200 mg of guaifenesin and in another example 400 mg of guaifenesin.
- Non-limiting examples of antihistamines can include chlorpheniramine, desloratadine, levocetirizine, diphenhydramine, doxylamine succinate, triprolidine, clemastine, pheniramine, brompheniramine, dexbrompheniramine, loratadine, cetirizine and fexofenadine, amlexanox, alkylamine derivatives, cromolyn, acrivastine, ibudilast, bamipine, ketotifen, nedocromil, omalizumab, dimethindene, oxatomide, pemirolast, pyrrobutamine, pentigetide, thenaldine, picumast, tolpropamine, ramatroban, repirinast, suplatast tosylate aminoalkylethers, tazanolast, bromodiphenhydramine, tranilast, carbinoxamine,
- the liquid composition can comprise from about 0.01% to about 0.1% antihistamine, in another example from about 0.02% to about 0.07% antihistamine, and in another example from about 0.03% to about 0.05% antihistamine.
- the antihistamine can be doxylamine succinate and a dose of liquid medication can contain 12.5 mg doxylamine succinate.
- the antihistamine can be chlorpheniramine In one example a dose can contain 2 mg of chlorpheniramine and in another example a dose can contain 4 mg of chlorpheniramine
- the antihistamine can be PE. In one example a dose can contain 5 mg PE, in another example 10 mg PE, and in another example 20 mg PE.
- the antihistamine can be PSE. In one example a dose can contain 120 mg PSE and in another example 30 mg PSE.
- Non-limiting examples of antitussives can include DXM, codeine, chlophedianol, levodropropizine, and combinations thereof.
- the liquid medication can comprise from about 0.01% to about 0.2% antitussive, in another example from about 0.025% to about 0.1%, and in another example from about 0.04% to about 0.075% antitussive.
- the antitussive can be selected from the group consisting of DXM, chlophedianol, and combinations thereof.
- a dose can comprise 15 mg DXM, in another example 20 mg DXM, and in another example 30 mg DXM.
- a dose can comprise 12.5 mg chlophedianol.
- Non-limiting examples of pain relievers can include APAP, ibuprofen, ketoprofen, diclofenac, naproxen, aspirin, and combinations thereof.
- the liquid medication can comprise from about 0.5% to about 3.5% pain reliever, in another example from about 1% to about 3% pain reliever, and in another example from about 1.5% to about 2% pain reliever.
- the pain relievers can include APAP, ibuprofen, naproxen, or combinations thereof.
- a dose can comprise 325 mg to 500 mg APAP, in another example 200 mg ibuprofen, and in another example, 200 mg naproxen.
- the liquid medication can further comprise a stimulant such as caffeine.
- the liquid medication can comprise one or more MSR cold/flu actives, in another example two or more MSR cold/flu actives, in another example three or more MSR cold/flu actives, and in another example four or more MSR cold/flu actives.
- the liquid medication can comprise exactly one MSR cold/flu active, in another example exactly two MSR cold/flu actives, in another example exactly three MSR cold/flu actives, and in another example exactly four MSR cold/flu actives.
- the liquid medication can comprise APAP, doxylamine succinate, DXM, and PE.
- the active can be a plant-derived materials.
- plant-derived materials can include those used in traditional native American, Chinese, Aryuvedic and Japanese medicine, including flowers, leaves, stems and roots of plants as well as extracts and isolated active components from the flower, leaves, stems, and roots of plants.
- Plant and Animal based oils and esters such as Omega-3-fatty acids and alkyl esters thereof; Vitamins (including but not limited to provitamin and all forms of Vitamins C, D, A, B, E, and combinations thereof).
- Non-limiting examples of fibers and analogous carbohydrate polymers can include pectins, psyllium, guar gum, xanthan gum, alginaes, gum arabic, fructo-oligosaccharides, inulin, agar, beta-glucans, chitins, dextrins, lignin, celluloses, non-starch polysaccharides, carrageenan, reduced starch, and mixtures and/or combinations thereof;
- Prebiotics Non-limiting examples of prebiotics suitable for use in the compositions and methods can include psyllium, fructo-oligosaccharides, inulin, oligofructose, galacto-oligosaccharides, isomalto-oligosaccharides, xylo-oligosaccharides, soy-oligosaccharides, gluco-oligosaccharides, mannan-oligosaccharides, arabinogalactan, arabinxylan
- Non-limiting examples of probiotic bacteria suitable for use herein can include strains of Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus bifidus, Lactobacillus casei, Lactobacillus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus delbruekii, Lactobacillus thermophilus, Lactobacillus fermentii, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus brevis, Lactobacillus paracasei, Lactobacillus gasseri, Pediococcus cerevisiae, Bifidobacterium longum, Bifidobacterium infantis, B
- Non-limiting examples of minerals, metals, and elements useful in the systems of the present invention include: zinc, iron, calcium, iodine, copper and selenium.
- the minerals, metals and/or elements can be on or in a suitable carrier, and comprise from about 1% to about 50% by weight and alternatively from about 2% to about 30%, by weight of the composition comprising the mineral, metal or element and the carrier.
- the active can be a gastrointestinal active.
- gastrointestingal actives can include anti-diarrheal actives, laxatives, anti-nausea and anti-emetic actives, anti-flattulents, proton pump inhibitors, anti-inflammatory gastrointestinal actives, rafting agents, and combinations thereof.
- Non-limiting examples of anti-diarrheal actives can include loperamide, bismuth-containing compositions, bismuth subsalicylate, colloidal bismuth subcitrate, bismuth subcitrate, kaolin, pectin, clays such as attapulgite, activated charcoal, and combinations thereof.
- Non-limiting examples of laxatives can include fiber, resistant starch, resistant maltodextrin, pectin, cellulose, modified cellulose, polycarophil, senna, sennosides, bisacodyl, sodium phosphate, docusate, magnesium citrate, mineral oil, glycerin, aloe, castor oil, magnesium hydroxide, and combinations thereof
- Non-limiting examples of anti-nausea and anti-emetic actives can bismuth containing compositions including bismuth subsalicylate, phosphated carbohydrates, diphenhydramine, cyclizine, meclizine, and combinations thereof; non-limiting examples of antacids can include sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, magnesium silicates, alginic acids, sodium alginate, magaldrate, and combinations thereof.
- Non-limiting examples of anti-flattulents can include simethicone, activated charcoal, lactase, alpha-galactosidase enzymes, and combinations thereof; non-limiting examples of H2 receptor antagonists can include famotidine, ranitidine, ciemtidine, nitazidine, and combinations thereof.
- Non-limiting examples of proton pump inhibitors can include omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, and combinations thereof.
- a non-limiting example of an anti-inflammatory gastrointestinal active can include mesalamine.
- Non-limiting examples of rafting agents can include alginates, pectins and polysaccharides.
- the cells were further cultured according to the following procedure.
- the cells were grown in a Corning® cell culture flask, with a surface area of 75 cm 2 , a canted neck, and a 0.2 ⁇ m Vent cap (Catalog# 430641, available from VWR International, Bridgeport, N.J., USA) at 37° C. using a growth medium containing 500 mL of Iscove's Modified Dulbecco's Media (IMDM), 100 mL of Ham's F12 Nutrient Mixture, 60 mL Fetal Bovine Serum (FBS), and 150 ⁇ g/mL Penicillin-Streptomycin cocktail (all growth media components available from Life Technologies, Grand Island, N.Y., USA).
- IMDM Iscove's Modified Dulbecco's Media
- FBS Fetal Bovine Serum
- Penicillin-Streptomycin cocktail all growth media components available from Life Technologies, Grand Island, N.Y., USA.
- the cells After the cells reach 80-90% confluence, which generally takes about seven days of cultivation, the cells were released by adding 3 mL of Gibco® Trypsin-EDTA (0.05%) solution (available from Life Technologies) at 37° C. in couple of minutes, followed by adding 12 mL of cell growth medium to deactivate trypsin. Then the cells were diluted in the growth medium at approximately 250,000 cells/mL. Next, 100 ⁇ l volume of cell suspension containing 20,000 to 30,000 cells were seeded into each well of a Falcon® 96 Well Black with Clear Flat Bottom TC-Treated Imaging Plate (REF # 353219, available from VWR International, Bridgeport, N.J., USA) and the cells are grown overnight.
- Gibco® Trypsin-EDTA 0.05%) solution (available from Life Technologies) at 37° C. in couple of minutes, followed by adding 12 mL of cell growth medium to deactivate trypsin. Then the cells were diluted in the growth medium at approximately 250,000 cells/mL. Next,
- the Calcium-6QF solution was made by dissolving the contents of one vial of Calcium-6QF (available from Molecular Devices, Sunnyvale, Calif., USA) in 20 mL of assay buffer, which contains Hank's Balanced Salt Solution (HBSS) with 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (both components are available from Life Technologies). The plate was then incubated at 37° C. for 105 min and at room temperature for 15 min.
- HBSS Hank's Balanced Salt Solution
- HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- the 96-well plate is placed in a FLIPR® Tetra High Throughput Cellular Screening System (available from Molecular Devices) and 20 ⁇ L of working solution, as described below, are added to each well.
- the fluorescence signal was read continuously for 5 min, where the excitation and emission wave lengths used were 488 nM and 510 nM respectively. The peak value and/or area under the curve after five minutes was calculated and recorded.
- test material was diluted with the assay buffer.
- test materials can include, but are not limited to GG solutions, PG solutions, 1,3-PPD solutions, full formulations such as those in Example 4 and 5, and combinations thereof.
- the amount of assay buffer varies depending on the desired final concentration, which occurs when the test material is in the wells. For example, if the test material is GG, it can be desirable to have a final concentration of 2 mM. Thus, a 12 mM working solution is made and when it is added to the wells, the concentration is further reduced to a final concentration of 2 mM.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A liquid medication with reduced bitterness containing a drug active and polyquaternium-2, polyquaternium-17, and/or polyquaternium-18.
Description
- The present invention relates to a liquid medication comprising a low molecular weight polyquaternium to modulate bitterness, more particularly a low level of polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 to modulate bitterness.
- There are five recognized taste sensations, sweet, salty, sour, bitter, and umami. Many people dislike things that are overly bitter and perceive it is as unpleasant, sharp, or otherwise disagreeable. Bitterness is the most sensitive of the tastes and it is thought to be a defense mechanism to protect the body against ingestion of toxic substances, as a large number of natural bitter compounds are known to be toxic.
- However many medications, especially liquid medications, have a bitter taste associated with them due to the drug actives and excipients. Medications often contain flavors and sweeteners to mute the bitterness associated with the actives and excipients. Despite these efforts, many medications still possess an unpleasant taste and/or after taste. This causes some consumers to avoid and/or dread taking medications due to the unpleasant taste.
- Thus, there is a need for a medication, in particular a liquid medication, with reduced bitterness.
- A liquid medication with reduced bitterness comprising: (a) a drug active; and (b) a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof.
- A liquid medication with reduced bitterness comprising: (a) a drug active selected from the group consisting of guaifenesin, phenytoin, omeprazole, cetirizine, jambu, acetaminophen, and combinations thereof; (b) a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof; wherein an overall bitterness is reduced by at least about 40% as compared to an identical composition without the polyquaternium as determined by the in vitro Assay for Taste Receptors; and wherein an overall bitterness is less than about 6500 fluorescence units as determined by the in vitro Assay for Taste Receptors.
- A dose of liquid medication with reduced bitterness comprising: (a) at least about 200 mg guaifenesin; (b) from about 0.05% to about 0.2% of a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof; wherein a Descriptive Profile Panel of in mouth bitter is reduced by at least about 25% as compared to an in mouth bitter of an identical composition without the polyquaternium.
- While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter of the present invention, it is believed that the invention can be more readily understood from the following description taken in connection with the accompanying drawings, in which:
-
FIG. 1A shows the molecular structure for polyquaternium-2; -
FIG. 1B shows the molecular structure for polyquaternium-17; -
FIG. 1C shows the molecular structure for polyquaternium-18; -
FIG. 2 compares the modulation of bitterness of solutions with different water soluble polymers in an Assay for Taste Receptors; -
FIG. 3 compares the modulation of bitterness of solutions with different water soluble polymers in an Assay for Taste Receptors; -
FIG. 4A compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors; -
FIG. 4B compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors; -
FIG. 4C compares the modulation of bitterness of solutions containing an active and a concentration of polyquaternium-2 in an Assay for Taste Receptors; -
FIG. 4D compares the modulation of bitterness of solutions containing an active or an excipient and a concentration of polyquaternium-2 in an Assay for Taste Receptors; -
FIG. 5 compares the modulation of bitterness of full formulations containing one or more actives and excipients in an Assay for Taste Receptors; -
FIG. 6 shows the Descriptive Profile Panel (DPP) bitter intensity of six different compositions containing a high fructose corn syrup (HFCS) base, guaifenesin, and different concentrations of polyquaternium-2; and -
FIG. 7 shows the Descriptive Profile Panel (DPP) bitter intensity of two examples that both contain four actives and one example contains polyquaternium-2. - Many medications, especially liquid medications, have a bitter taste associated with them due to the drug actives and excipients. It has been surprisingly found that polyquaternium-2 can significantly modulate the bitterness in liquid medications.
- Several polymers, including other polyquats, were tested in vitro taste bud cell assays to determine whether they may serve as a bitter blocker. Polyquaternium-2 modulated the bitterness of guaifenesin (GG) in the cell assays better than any other polymer, including the polyquats which have a similar chemical structure. Polyquaternium-17 and/or polyquaternium-18 are structurally analogous to polyquternium-2 and can be used instead of or in combination with polyquaternium-2.
- Although polyquaternium-2 significantly reduced the bitterness of GG, one of the most bitter actives, based on the in vitro assays, it does not modulate the bitterness of all actives to the same extent. For instance, polyquaternium-2 significantly modulated the bitterness of phenytoin, omeprazole, jambu extract and acetaminophen (APAP), but had little effect on bitter actives such as dicyclomine, hydroxyzine, promethazine, doxepin, and diphenhydramine.
- Furthermore, it was surprisingly found that polyquaternium-2 modulated bitterness better at the relatively low concentration of about 0.1%, as compared to higher concentrations.
- As used herein, “dose” refers to a volume of medication, such as liquid medication, containing an amount of a drug active suitable for administration on a single occasion, according to sound medical practice. A dose can be orally administered. In one example, a dose can be about 30 mL, in another example about 25 mL, in another example about 20 mL, in another example about 15 mL, and in another example about 10 mL. In another example, a dose of liquid medication can be from about 10 mL to about 75 mL, in another example from about 15 mL to about 50 mL, in another example from about 25 mL to about 40 mL, and in another example from about 28 mL to about 35 mL. The concentration of active ingredients can be adjusted to provide the proper doses of actives given the liquid dose size. In one example, the dose is intended to be administered every 4 hours, in another example every 6 hours, in another example every 8 hours, and in another example every 12 hours.
- As used herein, “medication” refers to medications, such as pharmaceuticals, including prescription medications, over-the-counter medications, behind-the-counter medications and combinations thereof. In some examples, a medication can be a supplement.
- As used herein, the articles “a” and “an” are understood to mean one or more of the material that is claimed or described, for example, “an active” or “a solvent”.
- The composition the present invention can contain, consist of, or consist essentially of, the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in dosage forms intended for use or consumption by humans.
- It has been found that polyquaternium-2 can be added to compositions, particularly liquid medications, to reduce bitterness. Polyquaternium-2 has the CAS Registry Number 68555-36-2 and the chemical name is Poly[bis(2-chloroethyl) ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] and is commercially available as Mirapol® A 15 (available from Rhodia, Cranbury, N.J.). The molecular structure for polyquaternium-2 is shown in
FIG. 1A . Polyquaternium-17 (CAS Registry Number 148506-50-7) and polyquaternium-18 (CAS Registry Number 113784-58-0) are structurally analogous to polyquaternium-2 and can be used in addition to or instead of polyquaternium-2 to modulate bitter. The molecular structure for polyquaternium-17 is shown inFIG. 1B and the molecular structure for polyquaternium-18 is shown inFIG. 1C . -
FIG. 2 compares the modulation of bitterness of a control solution comprising 2 mM guaifenesin (GG) with solutions comprising 2 mM GG and one of seven water soluble polymers at concentrations ranging from 0.33% to 0.01%. The results forFIG. 2 are from an in vitro Assay for Taste Receptors, as described hereafter. The cell cultures and assays provide an in vitro method to screen for bitterness that can mimic an in vivo response. - The water soluble polymers that were tested were as follows at concentrations ranging from 0.01% to 0.33%:
-
- Polyquaternium-6 commercially available as Mirapol® 100 [CAS# 26062-79-3] (available from Rhodia, Cranbery, N.J.)
- Polyquaternium-2 commercially available as Mirapol® A 15 [CAS# 68555-36-2] (available from Rhodia, Cranbury, N.J.)
- Polyquaternium-7 commercially available as Mirapol® 550 [26590-05-6] (available from Rhodia, Cranbury, N.J.)
- Polyquaternium-7 commercially available as Merquat™ 2200 [CAS# 26590-05-6] (available from Lubrizol, Deer Park, Tex.)
- Polyquaternium-16 commercially available as Luviquat® FC550 [CAS# 95144-24-4] (available from BASF, Florham Park, N.J.)
- Polyquaternium D16 commercially available as Luviquat® FC 905 [CAS# 95144-24-4] (available from Crescent Company, Islandia, N.Y.)
- Polyquaternium-44 commercially available as Luviquat® care polymer [CAS# 150599-70-5] (available from BOC Sciences, Shirley, N.Y.)
- The taste receptors were activated as described in the Assay for Taste Receptors herein. The observed activation is presented as a % of the control value. The control value is activation by a 2 mM GG solution with no added polymers. The results from this assay showed that only Polyquaternium-2 completely blocked the activation of taste cell receptors by GG. This is especially surprising, since GG is one of the most bitter actives used in liquid medications. Other polymers, including polyquaternium-6 and polyquaternium D16 (Luviquat® 905) also showed some reduction, however the modulation was not dose dependent.
-
FIG. 3 compares the modulation of bitterness of a solution comprising 2 mM GG with one of four water soluble polymers at concentrations ranging from 0.01% to 0.00003%. The four water soluble polymers were polyquaternium-6 (Mirapol® 100), polyquaternium-2 (Mirapol® A15), polyquaternium D16 (Luviquat® FC 550), and polyquaternium D16 (Luviquat® FC 905). The same Assay for Taste Receptor Method described herein and forFIG. 2 was used to generate the results forFIG. 3 . The lower concentrations of polymer were selected to help further differentiate the potential ability for the polymers to provide bitter blocking in vivo. - Again, polyquaternium-2 provided the greatest reduction in bitterness of the 2 mM GG solution. At 0.01%, the bitterness was reduced to less than 20% of the bitterness of the control. Furthermore, polyquaternium-2 was the only composition that showed dose dependent blocking.
- Since polyquaternium-2 was effective in blocking the bitterness in the Assay for Taste Receptors, it was desirable to understand if polyquaternium-2 was effective against all bitter actives or select bitter actives. As shown in
FIGS. 4A, 4B, and 4C , it was found that polyquaternium-2 only blocked certain bitter drug actives and had little to no effect on others. -
FIGS. 4A, 4B, and 4C compare the modulation of bitterness, if any, of solutions containing an active and a concentration of polyquaternium-2. The concentration of polyquaternium-2 ranges from 0.00041% to 0.1%. GG at a concentration of 2 mM without polyquaternium-2 is used as a control. The actives were selected because they are frequently used in medications and are known to be bitter. The results forFIGS. 4A, 4B, and 4C are from an in vitro Assay for Taste Receptors as described hereafter. -
FIG. 4A compares the modulation of bitterness, if any, of solutions comprising 250 μM active and a concentration of polyquaternium-2. The actives inFIG. 4A are dicyclomine, hydroxyzine, promethazine, doxepin, and 2 mM GG.FIG. 4A shows that polyquaternium-2 has at best a very weak bitter blocking activity on dicyclomine, hydroxyzine, promethazine, and doxepin. However,FIG. 4A does not show a dose dependent effect and thus polyquaternium-2 is probably not a specific blocker of these actives. - The actives in
FIG. 4B are 1 mM diltiazem, 2 mM phenytoin, and 1 mM diphenhydramine. Polyquaternium-2 blocked some of the bitterness of diltiazem, but it doesn't show a dose dependent effect and thus polyquaternium-2 is probably not a specific blocker for diltiazem. Polyquaternium-2 strongly blocked the bitterness from phenytoin and omeprazole and polyquaternium-2 had little or no effect on diphenhydramine - The actives tested in
FIG. 4C included 1 mM cetirizine, 1 mM enalapril, 0.25% jambu (Acmella oleracea) extract (commercially available as Jambu SE WS from Naturex™, South Hackensack, N.J.), and 10 mM acetaminophen (APAP). Polyquaternium-2 blocked some of the bitterness of cetirizine. Polyquaternium-2 did not show a dose dependent bitter blocking of enalapril. However, polyquaternium-2 shows a strong dose dependent effect on blocking jambu and APAP. -
FIG. 4D compares the modulation of bitterness, if any, of solutions containing an active or an excipient and 0.01% polyquaternium-2 in the in vitro Assay for Taste Receptors as described hereafter. The compositions tested were 5 mM pseudoephedrine hydrochloride, 2 mM terpin, 2.5 mM prednisolone, 2.5 mM famotidine, 0.5mM 1,10-phenanthroline, 0.5 mM erythromycin, 0.5 mM saccharin, 3% propylene glycol, and 2 mM GG was used as the control. Polyquaternium-2 modulated the bitterness in all of the compositions, including components that were very bitter, like 1,10-phenanthroline, saccharin, and propylene glycol. Surprisingly, polyquaternium-2 completely blocked the bitterness from saccharin and substantially reduced the bitterness of both propylene glycol and 1,10-phenanthroline. - In one example, polyquaternium-2 polyquaternium-17, and/or polyquternium-18 can reduce the bitterness of a drug active selected from the group consisting of GG, APAP, jambu extract, cetirizine, phenytoin, omeprazol, 1,10-phenanthroline, and combinations thereof.
-
FIG. 5 compares ten full formulations diluted to 0.617% with the same ten formulations diluted to 0.617% with 0.02% polyquaternium-2 the in vitro Assay for Taste Receptors as described hereafter. The formulations are described in Table 1 below.FIG. 6 also includes a formulation with 2 mM GG and 10 μM Ionomycin, calcium salt, which were both used as controls. -
TABLE 1 Dose Formulation Size Active Ingredients per Dose Excipients Hyland's ® 15 mL Allium cepa 6X, Hepar Citric acid, glycyrrhiza DEFEND Cold & sulfuris calcareum12X, extract, purified water, Cough Hydrastis canadensis 6X, sodium benzoate N.F., (Lot # 114220) Natrum Muriaticum 6X, vegetable glycerine. Phosphorus 12X, Pulsatilla 6X, Sulphur 12X PediaCare ® 5 mL Phenylephrine HCl (2.5 mg) Carboxymethylcellulose Decongestant sodium, citric acid, edetate (Lot # 18263) disodium, FD&C red #40, flavors, glycerin, sodium benzoate, sodium citrate, sorbitol, sucralose, water Chestal ® Honey 2 US tsp Antimonium tartaricum 6C, Citric acid, honey, purified (Lot # M0092897) (9.9 mL) Bryonia 3C, Coccus cacti water, sodium benzoate, 3C, Drosera 3C, sucrose Ipecacuanha 3C, Pulsatilla 6C, Rumex crispus 6C, Spongia tosta 3C, Sticta pulmonaria 3C Nature's Way ®, 7.5 mL Pelargonium sidoides 1X Alcohol (8.2%), fructose, Umcka ® natural menthol, natural ColdCare, Mint- spearmint flavor, purified Menthol Flavor water, vegetable-source (Lot # 125637) glycerin Nighttime Cold & 30 mL Acetaminophen (650 mg), Citric Acid, sodium citrate Flu Relief similar and Dextromethorphan HBr dihydrate, FD&C Blue #1, to Nyquil ® (30 mg) Red#40, purified water, without saccharin, ace sulfame Doxylamine potassium, sodium, propylene glycol, alcohol, PEG-8, high fructose corn syrup, flavor Nighttime Cold & 30 mL Acetaminophen (650 mg), Citric Acid, sodium citrate Flu Relief similar and Dextromethorphan HBr dihydrate, FD&C Blue #1, to NyQuil ® cherry (30 mg) Red#40, purified water, flavor without saccharin, ace sulfame Doxylamine potassium, sodium, propylene glycol, alcohol, PEG-8, high fructose corn syrup, flavor Nighttime Cold & 30 mL Acetaminophen (650 mg), Citric Acid, sodium citrate Flu Relief similar and Dextromethorphan HBr dihydrate, Red#40, flavor, to Alcohol-Free (30 mg) purified water, saccharin, ace NyQuil ® without sulfame potassium, sodium, Chlorpheniramine propylene glycol, sodium benzoate, Carboxymethylcellulose sodium, PEG-8, high fructose corn syrup DayQuil ® Cold & 30 mL Acetaminophen (325 mg), Citric Acid, FD&C Yellow Flu Relief Dextromethorphan HBr (10 No. 6, flavor, glycerin, (Lot # mg), and Phenylephrine HCl propylene glycol, purified 124917193U) (5 mg) water, saccharin sodium, sodium benzoate, sodium chloride, sodium citrate, sorbitol, sucralose, xantham gum DayQuil ® Severe 30 mL Acetaminophen (650 mg), Citric Acid, FD&C Yellow Guaifenesin (400 mg), No. 6, flavor, glycerin, Dextromethorphan HBr (20 propylene glycol, purified mg), and Phenylephrine HCl water, saccharin sodium, (10 mg) sodium benzoate, sodium chloride, sodium citrate, sorbitol, sucralose, xantham gum Mucinex ® Fast- 20 mL Dextromethorphan HBr (20 Anhydrous citric acid, Max ® DM Max mg) dextrose, (Lot # 1002471) Guaifenesin (400 mg) D&C Red #33, FD&C Red #40, flavors, glycerin, methylparaben, potassium sorbate, propylene glycol, propylparaben, purified water, saccharin sodium, sodium hydroxide, sucralose, xanthan gum - In the assays of
FIG. 6 , 0.02% polyquaternium-2 was effective in substantially reducing or completely reducing the bitterness in all of the full formulations. Polyquaternium-2 completely or almost completely reduced the bitter from Nature's Way® Umcka™ ColdCare, the Nighttime Cold & Flu Relief similar to Nyquil® without doxylamine, the Nighttime Cold & Flu Relief similar to Nyquil® cherry flavor without doxylamine, the Nighttime Cold & Flu Relief similar to Alcohol-Free NyQuil® without chlorpheniramine, and DayQuil®. The 0.02% polyquaternium-2 significantly reduced the bitterness of DayQuil® Severe and Mucinex® Fast-Max® DM Max. - In one example polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition by at least about 5% as compared to an identical composition without the polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter, in another example by at least about 10%, in another example by at least about 20%, in another example by at least about 30%, in another example by at least about 40%, in another example by at least about 50%, in another example by at least about 60%, in another example by at least about 65%, in another example by at least about 70%, in another example by at least about 75%, in another example by at least about 80%, in another example by at least about 85%, in another example by at least about 90%, in another example at least about 93%, in another example at least about 95%, in another example by at least about 97%, in another example by at least about 98%, in another example by at least about 99% and in another example by at least about 100%.
- In another example, polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition as compared to an identical composition without the polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter. In another example, polyquaternium-2, polyquaternium-17, and/or polyquternium-18 can reduce the overall bitterness of a composition as compared to a composition that contains GG and does not contain polyquaternium-2, polyquaternium-17, and/or polyquternium-18 as determined by the in vitro Assay for Taste Receptors as described hereafter.
- In another example, the composition can have an overall bitterness of less than about 9000 fluorescence units (FUs) as determined by the in vitro Assay for Taste Receptors as described hereafter, in another example less than about 8500 FUs, in another example less than 8000 FUs, in another example less than 7500 FUs, in another example less than about 7000 FUs, in another example less than about 6500 FUs, in another example less than about 6000 FUs, in another example less than about 5500 FUs, in another example less than about 5000 FUs, in another example less than about 4500 FUs, in another example less than about 4000 FUs, in another example less than about 3500 FUs, in another example less than about 3000 FUs, in another example less than about 2500 FUs, in another example less than about 2000 FUs, in another example less than about 1500 FUs, in another example less than about 1000 FUs, in another example less than about 750 FUs, in another example less than about 500 FUs, in another example less than about 350 FUs, in another example less than about 300 FUs, in another example less than about 250 FUs, in another example less than about 200 FUs, in another example less than about 150 FUs, in another example less than about 100 FUs, and in another example less than about 50 FUs.
-
FIG. 6 compares the bitterness, as determined by the DPP panel, of the examples described in the table below. The high fructose corn syrup (HFCS) base contains 46.7% HFCS stock, 5.9% PEG-400 (polyethylene glycol 400), 8.6% propylene glycol, 7.4% ethanol, and 30.07% water. Excipients, including propylene glycol, can be bitter and the polyquaternium-2 can block the bitterness of the excipients in the HFCS base. -
Example High Fructose Corn Syrup Base Polyquaternium-2 1 q.s. 0% 2 q.s. 1% 3 q.s. 0.3% 4 q.s. 0.1% 5 q.s. 0.03% 6 q.s. 0.01% - Each panelist sampled 10 mL of each example using a “swish-and-spit” approach and rated the formulation for perceived bitter intensity. The DPP panel includes panelists that are trained and validated in Spectrum™ Descriptive Analysis methodology and evaluate bitterness on a 60 point scale.
- It was surprisingly found that the Example 4, which contained 0.1% polyquaternium-2 was less bitter than Examples 2 and 3, which had higher levels of Polyquaternium-2. Examples 5 and 6 were also less bitter than Examples 2 and 3 and may still be acceptable to consumers.
-
FIG. 7 compares the bitterness, as determined by the DPP panel, of the following examples: -
- Example 7 was commercially available DayQuil® Severe (Lot # 3308171931, expiration date October 2015) which contains four actives: APAP (216.67 mg per 10 mL), GG (133.33 mg per 10 mL), phenylephrine HCl (PE) (3.33 mg per 10 mL), and dextromethorphan (DXM) (6.67 mg per 10 mL). DayQuil® Severe also contains the following excipients: citric acid, FD&C Yellow No. 6, flavor, glycerin, propylene glycol, purified water, saccharin sodium, sodium benzoate, sodium chloride, sodium citrate, sorbitol, sucralose, xanthan gum
- Example 8 was the DayQuil® Severe of Example 7 with the addition of 0.1% polyquaternium-2.
- The DPP panel for
FIG. 7 was conducted according to the procedure described herein forFIG. 6 . Polyquaternium-2 reduced the overall bitterness in mouth, after expectoration, and at three minutes. The in mouth bitter was reduced by about 50% and the after expectoration bitter was reduced by over 10%. The three minute bitter was only reduced slightly and there was not a noticeable difference in bitterness after ten minutes. However, it can be most important to reduce the bitterness when the composition is in the mouth and immediately after it has been expectorated because this is the time when the composition is most bitter and unpleasant to the consumer. - In one example, the DPP in mouth bitter is reduced by at least about 5% as compared to the in mouth bitterness of an identical composition without polyquaternium-2, polyquaternium-17, and/or polyquaternium-18, in another example by at least about 10%, in another example by at least about 15%, in another example by at least about 20%, in another example by at least about 25%, in another example by at least about 35%, in another example by at least about 40%, in another example by at least about 45%, and in another example by at least about 50%. In one example, the DPP after expectoration bitter is reduced by at least about 4% as compared to the in mouth bitterness of an identical composition without polyquaternium-2, polyquaternium-17, and/or polyquaternium-18, in another example by at least about 4%, in another example by at least about 10%, in another example the DPP after expectoration bitterness by at least about 15%, in another example by at least about 18%, in another example by at least about 20%, and in another example by at least about 22%.
- Polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can be added to compositions, in particular liquid pharmaceutical compositions. In one example, the composition contains from about 0.01% to about 1% polyquaternium-2, in another example from about 0.03% to about 0.3%, in another example from about 0.05% to about 0.2%, in another example from about 0.07% to about 0.15%, in another example from about 0.08% to about 0.13%, and in another example from about 0.09% to about 0.11%. In one example, the composition can contain about 0.1% polyquaternium-2. In another example, the composition can contain less than about 1% polyquaternium-2, in another example less than about 0.5%, in another example less than about 0.3%, in another example less than about 0.2%, in another example less than about 0.15%, and in another example less than about 0.12%.
- The compositions can include a variety of orally administered dosage forms. Non-limiting examples of dosage forms can include a liquid medication, particles suspended in a liquid formulation, a solid in a gelatin or foam, or a solid dose in the form of a tablet, powder, granules, pellets, microspheres, nanospheres, beads, or nonpareils, and combinations thereof. In one example, the dosage form is a liquid medication. Dosage forms can be orally administered and can be swallowed immediately, slowly dissolved in the mouth, or chewed.
- In one example, polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can be added to a medication intended for use by children. Children can be especially sensitive to bitter tastes and adding polyquaternium-2, polyquaternium-17, and/or polyquaternium-18 can make bitter medicines more palatable.
- Non-limiting examples of additional solvents can include water, ethanol, glycerol, propylene glycol, polyethylene glycol 400, polyethylene glycol 200, and mixtures thereof. In one example the medication comprises from about 40% to about 95% solvent, in another example from about 50% to about 80% solvent, and in another example from about 55% to about 60% solvent, and in another example from about 68% solvent to about 72% solvent.
- In one example, the medication can contain water and propylene glycol. In one example, the medication comprises from about 15% to about 80% water, in another example from about 25% to about 75% water, in another example from about 40% to about 70% water, in another example from about 35% to about 45% water, and in another example from about 57% to about 66% water. In another example, the medication can contain from about 1% to about 10% propylene glycol, in another example from about 2% to about 8% propylene glycol, and in another example from about 3% to about 6% propylene glycol. In another example, the medication can contain from about 5% to about 40% propylene glycol, in another example from about 15% to about 35% propylene glycol, and in another example from about 20% to about 30% propylene glycol. In another example, the medication can comprise from about 1% to about 15% ethanol, in another example from about 3% to about 12% ethanol, and in another example from about 6% to about 10% ethanol.
- The compositions can comprise a sweetener to provide sweetness and taste masking of the actives and excipients that provide a bitter character. In one example, the composition comprises from about 2% to 25% sweetener, in another example from about 5% to 20% sweetener, in another example from about 7% to 15% sweetener, and in another example from about 8% to 12% sweetener. Non-limiting examples of sweeteners can include nutritive sweeteners, sugar alcohols, synthetic sugars, high intensity natural sweeteners, and combinations thereof. Non-limiting examples of nutritive sweeteners can include fructose, galactose, and combinations thereof. In one example, the sweetener can be high fructose corn syrup.
- Non-limiting examples of sugar alcohols can include xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erthritol, glycerin, and combinations thereof. In one example the composition can comprise from about 1% to about 30% sugar alcohol, in another example from about 5% to about 28% sugar alcohol, in another example about 10% to about 25% sugar alcohol, and in another example about 15% to about 23% sugar alcohol. In one example the composition comprises from about 5% to about 20% sorbitol, in another example from about 7% to about 18% sorbitol, and in another example from about 10% to about 15% sorbitol. In another example, the composition comprises from about 3% to about 15% glycerin, in another example from about 5% to about 10% glycerin, and in another example from about 7% to about 9% glycerin.
- Non-limiting examples of synthetic sweeteners can include sodium saccharin, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, and mixtures thereof. In one example the composition can comprise from about 0.01% to about 0.5% artificial sweetener, in another example from about 0.1% to about 0.3% artificial sweetener, and in another example about 0.15% to about 0.25% artificial sweetener.
- Non-limiting examples of high intensity natural sweeteners can include neohesperidin dihydrochalcone, stevioside, rebaudioside A, rebaudioside C, dulcoside, monoammonium glycrrhizinate, thaumatin, and combinations thereof.
- The liquid composition can optionally include one or more sensates. Non-limiting examples of sensates can include cooling sensates, warming sensates, tingling sensates, and combinations thereof. Sensates can useful to deliver signals to the user.
- Non-limiting examples of cooling sensates can include WS-23 (2-Isopropyl-N,2,3-trimethylbutyramide), WS-3 (N-Ethyl-p-menthane-3-carboxamide), WS-30 (1-glyceryl-p-mentane -3-carboxylate), WS-4 (ethyleneglycol-p-methane-3-carboxylate), WS-14 (N-t-butyl-p-menthane-3-carboxamide), WS-12 (N-(4-,ethoxyphenyl)-p-menthane-3-carboxamide), WS-5 (Ethyl-3-(p-menthane-3-carboxamido)acetate, Menthone glycerol ketal (sold as Frescolat® MGA by Haarmann & Reimer), (−)-Menthyl lactate (sold as Frescolat® ML by Haarmann & Reimer), (−)-Menthoxypropane-1,2-diol(sold as Coolant Agent 10 by Takasago International), 3-(1-menthoxy)propane-1,2-diol, 3-(1-Menthoxy)-2-methylpropane-1,2-diol, (−)-Isopulegol is sold under the name “Coolact P® ” by Takasago International., cis & trans p-Menthane-3,8-diols(PMD38)—Takasago International, Questice® (menthyl pyrrolidone carboxylate), (1R,3R,4S)-3-menthyl-3,6-dioxaheptanoate—Firmenich, (1R,2S,5R)-3-menthyl methoxyacetate—Firmenich, (1R,2S,5R)-3-menthyl 3,6,9-trioxadecanoate—Firmenich, (1R,2S,5R)-menthyl 11-hydroxy-3,6,9-trioxaundecanoate—Firmenich, (1R,2S,5R)-3-menthyl (2-hydroxyethoxy)acetate—Firmenich, Cubebol—Firmenich, Icilin also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl-]-1,2,3,6-tetrahydropyrimidine-2-one), 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone, Frescolat ML—menthyl lactate, Frescolat MGA—menthone glycerin acetal, Peppermint oil, L-Monomenthyl succinate, L-monomenthyl glutarate, 3-1-menthoxypropane-1,2-diol—(Coolact 10), 2-1-menthoxyethanol (Cooltact 5), TK10 Coolact (3-1-Menthoxy propane-1,2-diol), Evercool™ 180 (N-(4-cyanomethylphenyl)-ρ-menthanecarboxamide)), and combinations thereof. In one example, the composition can comprise from about 0.005% to about 1% cooling sensate, in another example from about 0.05% to about 0.5% cooling sensate, and in another example from about 0.01% to about 0.25% cooling sensate.
- In one example, the cooling sensate can be EverCool™ 180 available from Givaudan of Cincinnati, Ohio, as a 5% solution of N-(4-cyanomethylphenyl)-ρ-menthanecarboxamide in a flavoring ingredient cool white grape, or as a 7.5% solution of N-(4-cyanomethylphenyl)-ρ-menthanecarboxamide in a flavor ingredient such as spearmint or peppermint.
- Non-limiting examples of warming sensates can include TK 1000,
TK 1 MM, Heatenol—Sensient Flavors, Optaheat—Symrise Flavors, Cinnamon, Capsicum, Capsaicin, Curry, FSI Flavors, Isobutavan, Nonivamide 60162807, Hotact VEE,Hotact 1 MM, piperine, optaheat 295 832, optaheat 204 656, optaheat 200 349, and combinations thereof. Warming sensates can be present from about 0.005% to about 2%, in another example from about 0.01% to about 1%, and in another example from about 0.1% to about 0.5%. - Non-limiting examples of tingling sensates can include sichuan pepper, hydroxy alpha sanshool, jambu extracts, spilanthol, and combinations thereof. In one example, tingling sensates can be present from about 0.005% to about 1%, in another example from about 0.01% to about 0.5%, and another example from about 0.015% to about 0.3%.
- The composition can comprise a flavoring ingredient. When present, flavoring ingredients are generally used in the compositions at levels of from about 0.001% to about 8%, by weight of the composition.
- Additional non-limiting examples of flavoring ingredients can include peppermint oil, corn mint oil, spearmint oil, oil of wintergreen, clove bud oil, cassia, sage, parsley oil, marjoram, lemon, lime, orange, mango, cis-jasmone, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, 5-ethyl-3-hydroxy-4-methyl-2(5H)-furanone, vanillin, ethyl vanillin, propenyl guaethol, heliotropine, 4-cis-heptenal, diacetyl, methyl-ρ-tert-butyl phenyl acetate, menthol, methyl salicylate, ethyl salicylate, 1-menthyl acetate, oxanone, alpha-irisone, methyl cinnamate, ethyl cinnamate, butyl cinnamate, ethyl butyrate, ethyl acetate, methyl anthranilate, iso-amyl acetate, iso-amyl butyrate, allyl caproate, eugenol, eucalyptol, thymol, cinnamic alcohol, octanol, octanal, decanol, decanal, phenylethyl alcohol, benzyl alcohol, alpha-terpineol, linalool, limonene, citral, maltol, ethyl maltol, carvone, menthone, β-damascenone, ionone, gamma decalactone, gamma nonalactone, gamma undecalactone and mixtures thereof. Generally suitable flavoring ingredients are those containing structural features and functional groups that are less prone to redox reactions. These include derivatives of flavouring ingredients that are saturated or contain stable aromatic rings or ester groups. In one example, the composition comprises from about 0.01% to about 1% flavoring ingredients, in another example from about 0.05% to about 0.5% flavoring ingredients, and in another example from about 0.1% to about 0.3% flavoring ingredients.
- The composition can optionally include one or more salivation agents. Non-limiting examples of salivation agents include formula (I):
- wherein R1 represents C1-C2 n-alkyl; R2 is 2-methyl-1-propyl and R3 is hydrogen, or R2 and R3 taken together is a moiety (designated by the dashed lines) having the formula —(CH2)— wherein n is 4 or 5, and combinations thereof.
- In an embodiment, the salivating agent comprises a material wherein R2 is 2-methyl-1-propyl and R3 is hydrogen, in another embodiment the salivating agent comprises a material wherein R1 is Cl n-alkyl, R2 is 2-methyl-1-propyl and R3 is hydrogen. In another embodiment, the salivating agent comprises trans-pellitorin, a chemical having a structure according to formula (II):
- In another embodiment, the salivation agent can include sodium bicarbonate, sodium chloride, trans-pellitorin, and combinations thereof. In one example, salivation agents can be present from about 0.05% to about 2%, in another embodiment from about 0.1% to about 1%, and in another example from about 0.25%% to about 0.75%.
- The liquid composition can be any color. Non-limiting examples of colors can include red, green, amber, orange, yellow, blue, pink, violet, turquoise, and combinations thereof. In one example, the composition is green. In another example, the liquid composition is clear.
- The composition can also comprise a dye that provides the color. Non-limiting examples dyes that may be used in the present invention include FD&C
blue # 1, FD&Cblue # 2, D&Cblue # 4, D&C blue #9, FD&Cgreen # 3, D&Cgreen # 5, D&C green #6, D&Cgreen # 8,D&C orange # 4,D&C orange # 5,D&C orange # 10, D&C orange #11, FD&Cred # 3, FD&Cred # 4, D&C red #6, D&C red #7, D&C red #17, D&C red #21, D&C red #22, D&C red #27, D&C red #28, D&Cred # 30, D&C red #31, D&C red #33, D&C red #34, D&C red #36, D&C red #39, FD&Cred # 40,D&C violet # 2, FD&Cyellow # 5, FD&C yellow #6, D&C yellow #7, Ext. D&C yellow #7, D&Cyellow # 8, D&Cyellow # 10, D&C yellow #11, and combinations thereof. In one example, the composition comprises from about 0.001% to about 0.1% dye, in another example from about 0.002% to about 0.05% dye, and in another example form about 0.003% to about 0.01% dye. - In one example, the composition comprises a buffer. The buffer can help maintain a constant pH within the liquid composition. In one example the liquid composition comprises from about 0.05% to about 2% buffer, in another example from about 0.1% to about 1% buffer, in another example from about 0.15% to about 0.5% buffer, and in another example from about 0.18% to about 0.25% buffer. Buffers can include acetate buffers, citrate buffers, and phosphate buffers. Non-limiting examples of buffers can include acetic acid, sodium acetate, citric acid, sodium citrate, monobasic sodium phosphate, dibasic sodium phosphate, sodium carbonate, sodium bicarbonate, succinic acid, sodium succinate, potassium dihydrogen phosphate, and phosphoric acid.
- In one example, the composition comprises a preservative. In one example the liquid composition comprises from about 0.01% to about 1% preservative, in another example from about 0.05% to about 0.5% preservative, in another example from about 0.07% to about 0.3% preservative, and in another example from about 0.08% to about 0.15% preservative. Non-limiting examples of preservatives can include benzalkonium chloride, ethylenediaminetetraacetic acid (EDTA), benzyl alcohol, potassium sorbate, parabens, benzoic acid, sodium benzoate, and mixtures thereof.
- In one example, the composition comprises a thickener. In one example the liquid composition comprises from 0.01% to 3% thickener, in another example 0.05% to 1.5% thickener, in another example 0.1% to 0.75% thickener, and in another example 0.12% to 0.3% thickener. Non-limiting examples of thickeners can include xanthan gum, carrageenan, polyacrylic acid, polyvinylpyrrolidone, cellulosic polymers including carboxymethycellulose, hydroxethylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, and combinations thereof.
- The liquid compositions can comprise one or more drug actives. In one example, the drug actives can be immediate release drug actives, extended release drug actives, or delayed release drug actives. In one example, the drug active can be formulated as particles and in another example the active can be formulated as coated beads.
- In one example, the drug active is a multi-symptom relief (MSR) cold/flu active which can be used to treat one or more cold/flu symptoms. MSR cold/flu actives can be used to treat a variety of cold/flu symptoms including nasal congestion, runny nose, sneezing, headache, dry cough, sore throat, sinus pressure or pain, chest congestion, muscle aches/pains, wet/chesty cough, fever, and combinations thereof. MSR cold/flu actives can include decongestants, expectorants, antihistamines, antitussives, pain relievers, and combinations thereof.
- In one example, MSR cold/flu actives can be formulated for daytime use or nighttime use. In one example, the liquid medication comprises instructions that direct a user to ingest the medication at night before bedtime.
- Non-limiting examples of expectorants can include guaifenesin, ambroxol, bromhexine, and combinations thereof. In one example, the expectorant can be guaifenesin. In one example a dose can comprise 200 mg of guaifenesin and in another example 400 mg of guaifenesin.
- Non-limiting examples of antihistamines can include chlorpheniramine, desloratadine, levocetirizine, diphenhydramine, doxylamine succinate, triprolidine, clemastine, pheniramine, brompheniramine, dexbrompheniramine, loratadine, cetirizine and fexofenadine, amlexanox, alkylamine derivatives, cromolyn, acrivastine, ibudilast, bamipine, ketotifen, nedocromil, omalizumab, dimethindene, oxatomide, pemirolast, pyrrobutamine, pentigetide, thenaldine, picumast, tolpropamine, ramatroban, repirinast, suplatast tosylate aminoalkylethers, tazanolast, bromodiphenhydramine, tranilast, carbinoxamine, traxanox, chlorphenoxamine, diphenylpyaline, embramine, p-methyldiphenhydramine, moxastine, orphenadrine, phenyltoloxamine, setastine, ethylenediamine derivatives, chloropyramine, chlorothen, methapyrilene, pyrilamine, talastine, thenyldiamine, thonzylamine hydrochloride, tripelennamine, piperazines, chlorcyclizine, clocinizine, homochlorcyclizine, hydroxyzine, tricyclics, phenothiazines, mequitazine, promethazine, thiazinamium methylsulfate, azatadine, cyproheptadine, deptropine, desloratadine, isothipendyl, olopatadine, rupatadine, antazoline, astemizole, azelastine, bepotastine, clemizole, ebastine, emedastine, epinastine, levocabastine, mebhydroline, mizolastine, phenindamine, terfenadine, tritoqualine, phenylephrine (PE), pseudophedrine (PSE) and combinations thereof.
- In one example the liquid composition can comprise from about 0.01% to about 0.1% antihistamine, in another example from about 0.02% to about 0.07% antihistamine, and in another example from about 0.03% to about 0.05% antihistamine. In one example, the antihistamine can be doxylamine succinate and a dose of liquid medication can contain 12.5 mg doxylamine succinate. In another example, the antihistamine can be chlorpheniramine In one example a dose can contain 2 mg of chlorpheniramine and in another example a dose can contain 4 mg of chlorpheniramine In another example, the antihistamine can be PE. In one example a dose can contain 5 mg PE, in another example 10 mg PE, and in another example 20 mg PE. In another example, the antihistamine can be PSE. In one example a dose can contain 120 mg PSE and in another example 30 mg PSE.
- Non-limiting examples of antitussives can include DXM, codeine, chlophedianol, levodropropizine, and combinations thereof. In one example the liquid medication can comprise from about 0.01% to about 0.2% antitussive, in another example from about 0.025% to about 0.1%, and in another example from about 0.04% to about 0.075% antitussive. In one example the antitussive can be selected from the group consisting of DXM, chlophedianol, and combinations thereof. In one example a dose can comprise 15 mg DXM, in another example 20 mg DXM, and in another example 30 mg DXM. In another example a dose can comprise 12.5 mg chlophedianol.
- Non-limiting examples of pain relievers can include APAP, ibuprofen, ketoprofen, diclofenac, naproxen, aspirin, and combinations thereof. In one example the liquid medication can comprise from about 0.5% to about 3.5% pain reliever, in another example from about 1% to about 3% pain reliever, and in another example from about 1.5% to about 2% pain reliever. In one example the pain relievers can include APAP, ibuprofen, naproxen, or combinations thereof. In one example a dose can comprise 325 mg to 500 mg APAP, in another example 200 mg ibuprofen, and in another example, 200 mg naproxen.
- In one example, the liquid medication can further comprise a stimulant such as caffeine.
- In one example, the liquid medication can comprise one or more MSR cold/flu actives, in another example two or more MSR cold/flu actives, in another example three or more MSR cold/flu actives, and in another example four or more MSR cold/flu actives. In one example, the liquid medication can comprise exactly one MSR cold/flu active, in another example exactly two MSR cold/flu actives, in another example exactly three MSR cold/flu actives, and in another example exactly four MSR cold/flu actives. In one example the liquid medication can comprise APAP, doxylamine succinate, DXM, and PE.
- In one example, the active can be a plant-derived materials. As used herein, non-limiting examples of plant-derived materials can include those used in traditional native American, Chinese, Aryuvedic and Japanese medicine, including flowers, leaves, stems and roots of plants as well as extracts and isolated active components from the flower, leaves, stems, and roots of plants. Plant and Animal based oils and esters such as Omega-3-fatty acids and alkyl esters thereof; Vitamins (including but not limited to provitamin and all forms of Vitamins C, D, A, B, E, and combinations thereof). Fibers: Non-limiting examples of fibers and analogous carbohydrate polymers can include pectins, psyllium, guar gum, xanthan gum, alginaes, gum arabic, fructo-oligosaccharides, inulin, agar, beta-glucans, chitins, dextrins, lignin, celluloses, non-starch polysaccharides, carrageenan, reduced starch, and mixtures and/or combinations thereof; Prebiotics: Non-limiting examples of prebiotics suitable for use in the compositions and methods can include psyllium, fructo-oligosaccharides, inulin, oligofructose, galacto-oligosaccharides, isomalto-oligosaccharides, xylo-oligosaccharides, soy-oligosaccharides, gluco-oligosaccharides, mannan-oligosaccharides, arabinogalactan, arabinxylan, lactosucrose, gluconannan, lactulose, polydextrose, oligodextran, gentioligosaccharide, pectic oligosaccharide, xanthan gum, gum arabic, hemicellulose, resistant starch and its derivatives, reduced starch, and mixtures and/or combinations thereof. Probiotics: Non-limiting examples of probiotic bacteria suitable for use herein can include strains of Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus bifidus, Lactobacillus casei, Lactobacillus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus delbruekii, Lactobacillus thermophilus, Lactobacillus fermentii, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus brevis, Lactobacillus paracasei, Lactobacillus gasseri, Pediococcus cerevisiae, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium animalis, Bifidobacterium pseudolongum, Bifidobacterium thermophilum, Bifidobacterium lactis, Bifidobacterium bulgaricus, Bifidobacterium breve, Bifidobacterium subtilis, Escherichia coli and strains of the genera including Bacillus, Bacteroides, Enterococcus (e.g., Enterococcus faecium) and Leuconostoc, and mixtures and/or combinations thereof.
- Minerals, metals and/or elements: Non-limiting examples of minerals, metals, and elements useful in the systems of the present invention include: zinc, iron, calcium, iodine, copper and selenium. When present, the minerals, metals and/or elements can be on or in a suitable carrier, and comprise from about 1% to about 50% by weight and alternatively from about 2% to about 30%, by weight of the composition comprising the mineral, metal or element and the carrier.
- In another example, the active can be a gastrointestinal active. Non-limiting examples of gastrointestingal actives can include anti-diarrheal actives, laxatives, anti-nausea and anti-emetic actives, anti-flattulents, proton pump inhibitors, anti-inflammatory gastrointestinal actives, rafting agents, and combinations thereof.
- Non-limiting examples of anti-diarrheal actives can include loperamide, bismuth-containing compositions, bismuth subsalicylate, colloidal bismuth subcitrate, bismuth subcitrate, kaolin, pectin, clays such as attapulgite, activated charcoal, and combinations thereof.
- Non-limiting examples of laxatives can include fiber, resistant starch, resistant maltodextrin, pectin, cellulose, modified cellulose, polycarophil, senna, sennosides, bisacodyl, sodium phosphate, docusate, magnesium citrate, mineral oil, glycerin, aloe, castor oil, magnesium hydroxide, and combinations thereof
- Non-limiting examples of anti-nausea and anti-emetic actives can bismuth containing compositions including bismuth subsalicylate, phosphated carbohydrates, diphenhydramine, cyclizine, meclizine, and combinations thereof; non-limiting examples of antacids can include sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, magnesium silicates, alginic acids, sodium alginate, magaldrate, and combinations thereof.
- Non-limiting examples of anti-flattulents can include simethicone, activated charcoal, lactase, alpha-galactosidase enzymes, and combinations thereof; non-limiting examples of H2 receptor antagonists can include famotidine, ranitidine, ciemtidine, nitazidine, and combinations thereof.
- Non-limiting examples of proton pump inhibitors can include omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, and combinations thereof.
- A non-limiting example of an anti-inflammatory gastrointestinal active can include mesalamine.
- Non-limiting examples of rafting agents can include alginates, pectins and polysaccharides.
- Human fungiform taste bud cells were isolated from tongues of humans as described in Ozdener, Mehmet, and Nancy Rawson. “Primary Culture of Mammalian Taste Epithelium.” Methods in Molecular Biology; 2013; 945: 95-107.
- Then the cells were further cultured according to the following procedure. The cells were grown in a Corning® cell culture flask, with a surface area of 75 cm2, a canted neck, and a 0.2 μm Vent cap (Catalog# 430641, available from VWR International, Bridgeport, N.J., USA) at 37° C. using a growth medium containing 500 mL of Iscove's Modified Dulbecco's Media (IMDM), 100 mL of Ham's F12 Nutrient Mixture, 60 mL Fetal Bovine Serum (FBS), and 150 μg/mL Penicillin-Streptomycin cocktail (all growth media components available from Life Technologies, Grand Island, N.Y., USA).
- After the cells reach 80-90% confluence, which generally takes about seven days of cultivation, the cells were released by adding 3 mL of Gibco® Trypsin-EDTA (0.05%) solution (available from Life Technologies) at 37° C. in couple of minutes, followed by adding 12 mL of cell growth medium to deactivate trypsin. Then the cells were diluted in the growth medium at approximately 250,000 cells/mL. Next, 100 μl volume of cell suspension containing 20,000 to 30,000 cells were seeded into each well of a Falcon® 96 Well Black with Clear Flat Bottom TC-Treated Imaging Plate (REF # 353219, available from VWR International, Bridgeport, N.J., USA) and the cells are grown overnight.
- After the overnight cultivation, the cell culture media was removed by aspiration. Then, 100 μL of Calcium-6QF solution was added to each well. The Calcium-6QF solution was made by dissolving the contents of one vial of Calcium-6QF (available from Molecular Devices, Sunnyvale, Calif., USA) in 20 mL of assay buffer, which contains Hank's Balanced Salt Solution (HBSS) with 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (both components are available from Life Technologies). The plate was then incubated at 37° C. for 105 min and at room temperature for 15 min. Then the 96-well plate is placed in a FLIPR® Tetra High Throughput Cellular Screening System (available from Molecular Devices) and 20 μL of working solution, as described below, are added to each well. The fluorescence signal was read continuously for 5 min, where the excitation and emission wave lengths used were 488 nM and 510 nM respectively. The peak value and/or area under the curve after five minutes was calculated and recorded.
- In order to form the working solution, the test material was diluted with the assay buffer. Examples of test materials can include, but are not limited to GG solutions, PG solutions, 1,3-PPD solutions, full formulations such as those in Example 4 and 5, and combinations thereof. The amount of assay buffer varies depending on the desired final concentration, which occurs when the test material is in the wells. For example, if the test material is GG, it can be desirable to have a final concentration of 2 mM. Thus, a 12 mM working solution is made and when it is added to the wells, the concentration is further reduced to a final concentration of 2 mM. In another example, in order to make a working solution for Examples 4 and 5, and other full formulations, 1 mL of the example is added to 27 mL of assay buffer to form the working solution and then it is added to the wells for an overall reduction of 162 fold.
- While the specification concludes with the claims particularly pointing and distinctly claiming the invention, it is believed that embodiments of the present invention will be better understood from this description. In all embodiments of the present invention, all weight percentages are by weight of the total composition, unless specifically stated otherwise. All ratios are weight ratios, unless specifically stated otherwise. All ranges are inclusive and combinable. The number of significant digits conveys neither limitation on the indicated amounts nor on the accuracy of the measurements. All measurements are understood to be made at 25° C. and at ambient conditions, where “ambient conditions” means conditions under about one atmosphere of pressure and at about 50% relative humidity. All such weights as they pertain to listed ingredients are based on the active level and do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified.
- The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm.”
- Every document cited herein, including any cross referenced or related patent or application and any patent application or patent to which this application claims priority or benefit thereof, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
- While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (18)
1. A medication with reduced bitterness comprising:
a. a drug active, wherein the drug active is selected from the group consisting of guaifenesin, phenytoin, omeprazole, cetirizine, jambu, acetaminophen, and combinations thereof; and
b. a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof.
2. The medication of claim 1 wherein the drug active comprises guaifenesin.
3. The mediation of claim 2 wherein the drug active further comprises acetaminophen.
4. The medication of claim 1 wherein the medication comprises from about 0.0001% to about 1% of the polyquaternium.
5. The medication of claim 1 wherein the medication comprises from about 0.001% to about 1% of the polyquaternium.
6. The medication of claim 1 wherein the medication comprises from about 0.03% to about 0.3% of the polyquaternium.
7. The medication of claim 1 wherein the medication comprises less than about 0.2% of the polyquaternium-2.
8. The medication of claim 1 wherein the medication is selected from a liquid, a tablet, a powder and combinations thereof.
9. The medication of claim 1 further comprising a sensate.
10. The medication of claim 1 wherein an overall bitterness is less than about 7000 fluorescence units as determined by the in vitro Assay for Taste Receptors.
11. A dose of medication with reduced bitterness comprising:
a. at least about 200 mg guaifenesin;
b. from about 0.05% to about 0.2% of a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-17, polyquaternium-18, and combinations thereof.
12. The dose of medication of claim 11 wherein the polyquaternium is polyquaternium-2.
13. The dose of medication of claim 11 further comprising an antihistamine, an antitussive, a pain reliever and combinations thereof.
14. The dose of medication of claim 113 further comprising from about 325 mg to about 500 mg of the pain reliever.
15. The dose of medication of claim 11 wherein the pain reliever is acetaminophen.
16. The dose of medication of claim 15 further comprising dextromethorphan hydrobromide and phenylephrine.
17. The dose of medication of claim 16 comprising about 5 mg phenylephrine.
18. The dose of medication of claim 16 comprising about 10 mg dextromethorphan hydrobromide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/421,467 US20170136126A1 (en) | 2014-02-27 | 2017-02-01 | Medication With A Reduced Bitter Taste Perception |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461945437P | 2014-02-27 | 2014-02-27 | |
US201462065843P | 2014-10-20 | 2014-10-20 | |
US14/633,160 US9592298B2 (en) | 2014-02-27 | 2015-02-27 | Medication with a reduced bitter taste perception |
US15/421,467 US20170136126A1 (en) | 2014-02-27 | 2017-02-01 | Medication With A Reduced Bitter Taste Perception |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/633,160 Continuation US9592298B2 (en) | 2014-02-27 | 2015-02-27 | Medication with a reduced bitter taste perception |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170136126A1 true US20170136126A1 (en) | 2017-05-18 |
Family
ID=52737387
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/633,160 Active US9592298B2 (en) | 2014-02-27 | 2015-02-27 | Medication with a reduced bitter taste perception |
US15/421,467 Abandoned US20170136126A1 (en) | 2014-02-27 | 2017-02-01 | Medication With A Reduced Bitter Taste Perception |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/633,160 Active US9592298B2 (en) | 2014-02-27 | 2015-02-27 | Medication with a reduced bitter taste perception |
Country Status (10)
Country | Link |
---|---|
US (2) | US9592298B2 (en) |
EP (1) | EP3110396B1 (en) |
CN (1) | CN106061469A (en) |
AU (1) | AU2015222882B2 (en) |
CA (1) | CA2937761A1 (en) |
ES (1) | ES2687257T3 (en) |
MX (1) | MX363148B (en) |
PL (1) | PL3110396T3 (en) |
RU (1) | RU2666531C2 (en) |
WO (1) | WO2015131000A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110327339A (en) * | 2019-08-07 | 2019-10-15 | 北京博达绿洲医药科技研究有限公司 | A kind of compound Dextromethorphan oral administration solution and its preparation method and application |
CN110302149A (en) * | 2019-08-07 | 2019-10-08 | 北京博达绿洲医药科技研究有限公司 | A kind of suitable 4-11 years old children taking anti-cold medicine and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763449A (en) * | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
DE10022077A1 (en) * | 2000-05-06 | 2001-11-08 | Henkel Kgaa | Compositions for use as hair or skin cosmetics or as cleaning agents for e.g. glass, metals, plastics or leather contain 2-furanone derivatives |
US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
US8450378B2 (en) * | 2006-02-09 | 2013-05-28 | Gojo Industries, Inc. | Antiviral method |
DE102010031291A1 (en) * | 2010-07-13 | 2012-01-19 | Henkel Ag & Co. Kgaa | Teeth-whitening mouthwash and mouthwash concentrates |
EP2641477B2 (en) | 2012-03-19 | 2022-06-08 | Symrise AG | Compositions of matter |
-
2015
- 2015-02-27 EP EP15712204.5A patent/EP3110396B1/en active Active
- 2015-02-27 CA CA2937761A patent/CA2937761A1/en not_active Abandoned
- 2015-02-27 CN CN201580009970.0A patent/CN106061469A/en active Pending
- 2015-02-27 MX MX2016011172A patent/MX363148B/en unknown
- 2015-02-27 RU RU2016131398A patent/RU2666531C2/en not_active IP Right Cessation
- 2015-02-27 AU AU2015222882A patent/AU2015222882B2/en not_active Ceased
- 2015-02-27 US US14/633,160 patent/US9592298B2/en active Active
- 2015-02-27 ES ES15712204.5T patent/ES2687257T3/en active Active
- 2015-02-27 PL PL15712204T patent/PL3110396T3/en unknown
- 2015-02-27 WO PCT/US2015/017895 patent/WO2015131000A1/en active Application Filing
-
2017
- 2017-02-01 US US15/421,467 patent/US20170136126A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2016131398A (en) | 2018-02-01 |
US20150238612A1 (en) | 2015-08-27 |
RU2666531C2 (en) | 2018-09-11 |
AU2015222882B2 (en) | 2017-06-22 |
CN106061469A (en) | 2016-10-26 |
ES2687257T3 (en) | 2018-10-24 |
MX2016011172A (en) | 2016-12-16 |
EP3110396B1 (en) | 2018-07-04 |
US9592298B2 (en) | 2017-03-14 |
AU2015222882A1 (en) | 2016-08-04 |
PL3110396T3 (en) | 2018-11-30 |
WO2015131000A1 (en) | 2015-09-03 |
CA2937761A1 (en) | 2015-09-03 |
MX363148B (en) | 2019-03-11 |
EP3110396A1 (en) | 2017-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3160592B1 (en) | Compositions with reduced bitter taste perception | |
US9974761B2 (en) | Medications for deposition on biological surfaces | |
US20090155189A1 (en) | Preparations, Methods and Kits Useful for the Treatment of Cough | |
AU2011215947B2 (en) | Liquid composition comprising a non-menthol cooling agent and a thickener for treating a respiratory symptom | |
US20170136126A1 (en) | Medication With A Reduced Bitter Taste Perception | |
AU2014216275B2 (en) | Anise flavored medication | |
CA3032750C (en) | Medication with improved taste and sensory experience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |